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“A heart is what a heart can do.” 




 “At this also my heart trembleth, and is moved out of its place.” 



















The work of this Thesis was initiated with an observational study in real-life clinical 
practice. We conducted a population-based evaluation of AF patients referred for their 
first elective CV. A total of 183 consecutive patients were included during the study 
period of one year. In 153 (84%) of the patients sinus rhythm (SR) was restored. Only 39 
(25%) of those 153 maintained SR for one year. Shorter duration of AF and the use of 
sotalol were the only characteristics associated with better restoration and maintenance of 
SR. During the one-year follow-up period 40% of the patients ended up in permanent AF, 
with the mean number of 1.6 cardioversions before this decision. Female gender and older 
age were associated with the acceptance of permanent AF. Longer duration of AF was 
associated with poorer outcome of the CV, and it also tended to increase the probability to 
be engaged in permanent AF, probably reflecting the negative atrial remodeling during the 
prolonged AF burden. 
 
The LIFE-trial was a prospective, randomised, double-blinded study that evaluated 
losartan and atenolol-based antihypertensive therapies on cardiovascular morbidity and 
mortality in patients with hypertension and left ventricular hypertrophy (LVH). 8,851 
patients with SR at baseline and without a history of AF were included in the analysis 
where the risk of new-onset AF was assessed. A total of 371 patients developed new-onset 
AF during the study period (4.8  1.0 years). Patients with new-onset AF had an increased 
risk of cardiac events, fatal or nonfatal stroke, and increased rate of hospitalisation for 
heart failure. Younger age, female gender, lower systolic blood pressure, lesser LVH in 
ECG and randomisation to losartan therapy were independently associated with lower 
frequency of new-onset AF. The mechanism behind the hindering effect of suppression of 
the renin-angiotensin-aldosterone system (RAAS) on AF was supposed to arise from 
regression of LVH and atrial remodeling. 
 
The impact of AF on morbidity and mortality was evaluated in a post-hoc analysis 
based on the data from the OPTIMAAL trial that compared losartan with captopril in 
patients with acute myocardial infarction (AMI) and evidence of left ventricular (LV) 
dysfunction. Of 5,477 randomised patients 655 had AF at baseline, and 345 patients 
developed new AF during the follow-up period, median 3.0 years. Older patients and 
patients with signs of more serious heart disease had and developed AF more often. 
Patients with AF at baseline had an increased risk of mortality (hazard ratio (HR) of 1.32) 
and stroke (HR 1.77). New-onset AF was associated with increased mortality (HR 1.82) 
and stroke (HR of 2.29).  
 
Atrial remodeling in AF patients as well as in experimental AF models is a well-
documented phenomenon, while the reverse remodeling after electrical CV has been much 
less investigated, and reverse remodeling has not been documented with MCG. The basis 
to estimate atrial reverse remodeling with magnetocardiography (MCG) was set with the 
assessment of the reproducibility of our MCG method. In 10 healthy volunteers and 9 





recorded in SR and the recordings were repeated at least 1 week apart (from 1 week to 6 
months). Reproducibility was best at 40-Hz filter (coefficient of variation of P-wave 
duration 3.3% and difference between the measurements 3.5 milliseconds on average) 
with no difference between patients and healthy subjects. 
 
Twenty-six patients with persistent AF and 24 age- and disease-matched controls were 
studied with the MCG method. Along with MCG, SAECG and echocardiography were 
registered. Immediately after the CV AF patients had longer P-wave duration and higher 
energy of the last portion of atrial signal (RMS40) in MCG, increased P-wave dispersion 
in SAECG and decreased pump function of the atria as well as enlarged atrial diameter in 
echocardiography compared to the controls. After one month in SR, P-wave duration in 
MCG still remained longer and left atrial (LA) diameter greater compared to the controls, 
while the other measurements had returned to the same level as in the control group. These 
results indicate that even though there is recovery in AF patients when SR is restored, this 
reversal is incomplete, and electrical and structural remodeling alterations predisposing to 
AF are seen. 
 
In conclusion, AF is not a rare condition in either general population or patients with 
hypertension or AMI, and it is also associated with increased risk of morbidity and 
mortality. The result of CV in clinical practice was poor and the proportion of patients 
assigned to permanent AF was high. Therefore, atrial remodeling that increases the 
likelihood of AF and also seems to be relatively stable has to be identified and prevented. 
MCG was found to be an encouraging new method to study electrical atrial remodeling 
and reverse remodeling. RAAS-suppressing medications appear to be the most promising 
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AC  = alternating current 
ACE(i)  = angiotensin-converting enzyme (inhibitor) 
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AFCL   = atrial fibrillation cycle length 
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ARB  = angiotensin receptor blocker 
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Atrial fibrillation (AF) is a cardiac arrhythmia characterised by rapid, irregular, 
unorganised electrical and mechanical activity of the atria. It is the most common 
sustained arrhythmia in man, with prevalence and incidence in general population of about 
1 - 2% and 0.2%, respectively, and it is associated with an increased mortality and risk of 
stroke (Feinberg et al. 1995, Benjamin et al. 1998, Fuster et al. 2006). The amount of AF 
increases strongly with age: while the prevalence in a population 50 years old is about 1%, 
it increases to about 10% in octogenarians (Feinberg et al. 1995, Benjamin et al. 1998, 
Fuster et al. 2006). More than 85% of AF patients have symptoms such as palpitations, 
shortness of breath and fatigue, AF patients having also significantly lower quality of life 
(Reynolds et al. 2006). Control of ventricular rate during AF, anticoagulation therapy to 
reduce the risk of stroke and restoration and maintenance of sinus rhythm (SR) are the 
three treatment lines considered in every AF patient, and also employed in most of them 
(Fuster et al. 2006).  
 
Because of the symptoms, restoration and maintenance of SR has in most cases been a 
goal in the treatment of AF. However, it has been shown during the last decade that the 
rhythm control strategy aiming for SR does not improve the survival of AF patients 
compared to the rate control strategy where SR is not aimed at. The rhythm control 
strategy can even be associated with higher mortality, especially if antiarrhythmic 
medications are used (Van Gelder et al. 2002, Wyse et al. 2002, Corley et al. 2004, Testa 
et al. 2005). Paradoxically, the presence of SR has, however, been associated with better 
survival, better exercise capacity and quality of life (Deedwania et al. 1998, Corley et al. 
2004, Opolski et al. 2004, Chung et al. 2005, Thrall et al. 2006). Therefore it seems that 
the treatment modalities  at least pharmacological ones  that are so far available on the 
market to restore and maintain SR are not safe enough. It has been asserted that 
transvenous AF ablation could be a safe and effective management for symptomatic AF, 
and it has also been associated with better survival of AF patients when compared in an 
unblinded, non-randomised setting to a patient group treated with antiarrhythmic agents 
(Pappone et al. 2003, Lubitz et al. 2008). In a recently published trial a new antiarrhythmic 
drug, dronedarone, increased the likelihood of SR and also decreased the number of 
cardiovascular deaths (Hohnloser et al. 2009). Those results might encourage attempts at 
restoration and maintenance of SR with newer and safer methods. 
 
The long-term results of the restoration and maintenance of SR are generally poor, 
perhaps reflecting the natural trend of AF to turn out to be more stable in an individual 
with AF (Kopecky et al. 1987). In prospective studies SR is maintained for a one-year 
period after electrical cardioversion (CV) in only about 20% of patients if antiarrhythmic 
agents are not used, while the percentage is about 40 - 50% with common antiarrhythmics, 
and about 70% with amiodarone (Fuster et al. 2006, Lafuente-Lafuente et al. 2007). The 
proportion of patients free from AF after one year of transvenous AF ablation has been 
about 70% in experienced centers when a substantial proportion of patients have had more 






regardless of the treatment given  for example CV, transvenous AF ablation or surgical 
AF ablation  some critical features seem to have a great influence on the number of 
patients who continue in AF or have an AF relapse. The most often repeated factors 
decreasing the likelihood of SR have been the age of the patient, the duration of AF and 
the size of the (left) atrium (Viko et al. 1923, Parkinson and Campbell 1929, Dittrich et al. 
1989, Van Gelder et al. 1996, Vasamreddy et al. 2004, Berruezo et al. 2007, Beukema et 
al. 2008). All these factors reflect or are surrogates of degeneration of atrial tissue; 
increased fibrosis during aging, atrium getting accustomed to AF during the arrhythmia 
(“AF begets AF”) and atrial distension because of AF itself or because of other 
cardiovascular diseases (Morillo et al. 1995, Wijffels et al. 1995, Allessie et al. 2002, 
Nattel 2002). This phenomenon is called atrial remodeling that is  at least to some extent 
 fundamental for AF to be initiated and especially to be maintained. 
 
AF tends to increase in frequency and duration. Therefore, and particularly because 
our traditional pharmacological approaches have only a limited safety-to-efficacy profile, 
so-called “up-stream therapies” are warranted and investigated in order to prevent primary 
events of AF and to decrease the frequency and duration of AF episodes. We do not have 
any treatment against aging, but suppression of the renin-angiotensin-aldosterone system 
(RAAS) seems to decrease the development of atrial fibrosis and also to prevent AF at 
least in patients with hypertension and heart failure (Li et al. 2001, Healey et al. 2005, 
Boldt et al. 2006, Burstein and Nattel 2008). When a patient gets symptomatic AF it is 
crucial that the treatments are started as soon as possible and SR is restored without any 
additional delay to prevent irreversible atrial remodeling from taking place (Van Gelder 
and Hemels 2006). 
 
The present series of studies is focused on atrial remodeling and atrial fibrillation, a 
common and fascinating arrhythmia that can be investigated from numerous perspectives. 
This work was started with a clinical evaluation of patients with persistent AF referred for 
elective CV. Thereafter the center of attention was to study the atrial remodeling and 
reverse remodeling after CV with MCG. Two post-hoc analyses studying AF of two 
prospective randomised trials evaluating RAAS suppressing medication are included to 







2 Review of the literature 
2.1 Short history of atrial fibrillation and its treatment 
The first documented observations of pulse have been found in ancient Chinese and 
Egyptian manuscripts. It was noticed very early that fast and irregular pulse was 
associated with poor prognosis (Lip and Beevers 1995, Lüderitz 2002a, Lüderitz 2002b). 
Perhaps the first description of AF is in The Yellow Emperor’s Classic of Internal 
Medicine (“Huang Ti Nei Ching Su Wen”). He was also a physician and is believed to 
have ruled China between 2697 and 2598 BC. (Lip and Beevers 1995). 
 
William Harvey (1578-1657) performed experimental work with animals, and the most 
valued of his work was the description of blood circulation. However, he is also probably 
the first to describe AF - “fibrillation of the auricles” – in animals, at least in recorded 
history (McMichael 1982, Flegel 1995). 
 
The first instrument to observe heartbeat was the stethoscope, invented by René 
Laennec (1781-1826), and soon after Laennec’s invention the association of irregular 
pulse and mitral stenosis was documented by Robert Adams (1791-1875) (Lip and 
Beevers 1995). Documentation of AF became possible with ECG. The first human ECG 
was recorded by Augustus Waller (1856-1922) in 1887, and in 1906 Willem Einthoven 
(1860-1927) described the first ECG of AF as “pulsus inaequalis and irregularis” (Lüderitz 
2002b, Fye 2006). Soon thereafter it was noticed that AF was “a common clinical 
condition” in patients with heart diseases (Lewis 1909). 
 
Explanation of the nature and concept of AF was advanced in the late 1800s and the 
early 1900s. Even though fibrillation or undulation of the atria was established in animal 
experiments, the similarity with the irregular pulse of a patient was not documented until 
1907 (Flegel 1995). In the first ECG recordings of AF atrial activity during AF was 
considered an artefact, but in 1909 it was noticed that there was irregular atrial electrical 
activity in AF. Furthermore, Thomas Lewis (1881-1945) noticed that atrial and ventricular 
rhythms were disordered and that the venous pulse was of ventricular type, lacking normal 
atrial contraction (Lewis 1909).  
 
In documented Western medical history, treatment of AF was first described by 
William Withering (1741-1799), who gave digitalis leaf to patients with heart failure. He 
discovered that irregular pulse became more regular and symptoms were relieved when 
digitalis was administered (Lip and Beevers 1995). With ECG a precise diagnosis of AF 
was possible and the treatment of patients became more accurate. As early as 1749 it was 
noticed that cinchona bark had a beneficial effect on irregular pulse, and in the late 1910s 
cardioversion of AF was performed with quinidine and documented with ECG (Lüderitz 






given us all the other antiarrhythmic drugs to restore and maintain SR and beta blocking 
agents to control the ventricular rate of AF. 
 
In the 1950s experimental work with defibrillators revealed that cardiac arrhythmias 
could be stopped with alternating current (AC) countershock (Zoll et al. 1956, Gibson et 
al. 1956, Lown et al. 1962, Gall and Murgatroyd 2007). This technique was, however, 
very robust, and the response was unpredictable. Bernard Lown made extensive 
experiments with defibrillation, and he observed that AC countershocks were associated in 
ECG with changes of acute myocardial infarction and caused mortality. Furthermore, he 
noticed that there was a vulnerable period in late systole, and a countershock given during 
this period caused ventricular arrhythmia. These inconveniences were solved with the 
implementation of QRS-complex synchronized direct current (DC) cardiac countershock 
and defibrillator (Lown et al. 1962). The procedure documented by Lown differs very 
little from that performed today, and the greatest progress since the 1960s has been the 







2.2 Epidemiology of atrial fibrillation 
2.2.1 Definitions 
The nomenclature and classification of AF has previously varied, causing large 
discrepancy between the studies published. At present, AF has been classified with good 
clinical relevance and simplicity, and the nomenclature has obtained international 
consensus (Lévy et al. 2003, Fuster et al. 2006). The currently accepted definition of AF 
as 1) paroxysmal AF – episodes that last less than or equal to 7 days and are self-
terminating, 2) persistent AF – episodes lasting usually more than 7 days and 3) 
permanent AF – long-lasting episodes where cardioversion has failed or is no longer 
attempted – was launched in 2001 in the ACC/AHA/ESC guidelines, which were updated 
in 2006 (Fuster et al. 2006). Most of the earlier studies did not make any distinction 
between the types of AF, or the type of AF was not documented. Therefore, if the type of 
AF is not established and published, the prevalence and incidence figures mentioned have 
to be considered as including all AF. So-called “lone atrial fibrillation” is defined as a 
status where an AF patient does not have any concomitant cardiovascular disease or 
diagnosis predisposing to AF (Fuster et al. 2006). 
2.2.2 Epidemiology of atrial fibrillation in general population 
2.2.2.1 Prevalence of AF in general population 
The first publication about the prevalence of AF in general population was written by 
Ostrander et al. They performed epidemiological investigation in the town of Tecumseh, 
Michigan, USA, where almost 90% of the total population had a complete medical 
examination with 12-lead ECG (Ostrander et al. 1965). More than 5,000 adult citizens 
were evaluated, 22 of whom (0.4%) had AF. They also found that AF was more prevalent 
among older citizens, and four of the six who had AF and were less than 60 years old had 
rheumatic heart disease.  
 
The ATRIA study was a large-scale evaluation performed within Kaiser Permanente in 
Northern California. This health care organisation takes care of nearly 3 million members. 
The prevalence of AF in population ≥ 20 years old was 0.95%, comprising almost 18,000 
AF patients. Among patients older than 55 years, AF appeared to be more common in 
white (2.2%) than in black (1.5%) patients (Go et al. 2001). Although the population 
served by the organisation was vast, there were some limitations in this study. First, the 






some skewness for example in household income compared to Northern California 
population as a whole. Furthermore, they excluded patients with transient AF and 
hyperthyroidism. Based on the determined prevalence in the studied population Go et al. 
estimated that during the cohort assembly period in the late 1990s there were nearly 2.3 
million US adults with non-transient AF. Furthermore, they estimated that this number 
would increase 2.5-fold to more than 5.6 million by the year 2050 because of the increase 
in the number of elderly persons (Go et al. 2001). 
 
One study in England and Wales and another in Scotland have estimated the 
prevalence of AF in general practice settings in Great Britain (Majeed et al. 2001, Murphy 
et al. 2007). These studies also had a very remarkable size of registered populations served 
by the National Health Service; 1.4 million and 360,000, respectively. The prevalence of 
AF in England and Wales was 12.1/1,000 in men and 12.7/1,000 in women, the 
corresponding figures in Scotland being 9.4/1,000 and 7.9/1,000 (Majeed et al. 2001, 
Murphy et al. 2007).  
 
The main limitation in studies with patients of health care registers is that patients with 
asymptomatic AF are not included. The question of asymptomatic AF was recently 
enlightened by Fitzmaurice et al. who documented that screening in order to find all the 
AF patients could increase the prevalence of AF in general practice environment about 
1.6-fold (Fitzmaurice et al. 2007).  
 
The Framingham Heart Study (FHS) is a large-scale follow-up study based on cohorts 
in Framingham, Massachusetts, USA. The study started in the late 1940s with more than 
5,000 adult subjects, and AF has been one of the main topics evaluated over the decades, 
giving us numerous publications describing the epidemiology of AF (complete biography: 
www.framinghamheartstudy.org). The main findings of FHS regarding the prevalence of 
AF have been that AF is seen in 0.5% at age 50-59 years and in up to almost 9% in 
octogenarians, the prevalence of AF is increasing, and men have an about 1.5-fold greater 
age-adjusted risk of AF than women (Kannel et al. 1998). Figure 1 shows the prevalence 
of AF in several epidemiologic studies in general population; the studies are listed in 























Figure 1. The prevalence of AF in ten epidemiologic studies in general population. The data of 
those studies are given in Table 4 in the Appendix. Each study is presented with its 
own symbol, and the mean trend line is depicted. 
2.2.2.2 Incidence of AF in general population 
Many of the studies mentioned in the previous chapter have also had databases to explore 
the incidence of AF. However, since the incidence of a disease is a time-dependent 
subject, cross-sectional study design is not valid, and a follow-up of the population studied 
is needed. Another method to evaluate the incidence of AF is to screen for a “new AF”, 
which is defined as AF not diagnosed earlier in a particular patient. 
 
Cardiovascular Health Study (CHS) studied a population ≥ 65 years old and also had a 
follow-up aspect. During their average follow-up of 3.3 years the incidence of AF was 
19.2 per 1,000 person-years (Psaty et al. 1997). The Mayo Clinic in Rochester, Minnesota 
serves almost completely the surrounding Olmsted County, and the incidence of AF in 
that population has risen from 3.0 per 1,000 person-years to 3.7 per 1,000 person-years 
from 1980 to 2000 (Miyasaka et al. 2006). Based on these results Miyasaka et al. 
estimated the number of AF patients in the US to be 12 million by 2050, which is more 
than 2-fold assumed by the ATRIA study investigators, even if the age-adjusted incidence 
of AF remains stable (Go et al. 2001, Miyasaka et al. 2006). 
 
The European perspective on AF incidence in general health care setting is based on 
British health care databases. In a Scottish study the incidence of AF was 0.9 per 1,000 
person-years in patients older than 45 years (Murphy et al. 2007). Ruigómez et al. had a 
very large General Practice population of approximately 3 million residents (Ruigómez et 






in residents aged 40-89 years (Ruigómez et al. 2002). However, those studies were cross-
sectional, without any follow-up, and therefore they most probably underestimate the real 
incidence of AF in those populations. For that reason they are not included in Figure 2 but 
the data are given in Table 5. 
 
The Framingham Heart Study (FHS) has the first and longest history of monitoring a 
cohort at risk of AF. In 1994 it was published that of the population of about 4,700 
citizens older than 55 years, 264 men and 298 women had developed new AF during up to 
38 years of follow-up. Hence the incidence of AF during this very long period was 12% 
(Benjamin et al. 1994). In 2004 they published two reports revealing the increase of AF 
incidence based on the FHS database. In a paper by Wang et al. AF incidence was 10% 
during a 13.7-year follow-up time, and another article by Lloyd-Jones et al. demonstrated 
the lifetime risk of development of AF being 1 in 4 in the Framingham population (Wang 
et al. 2004, Lloyd-Jones et al. 2004). Figure 2 depicts the incidence of AF in several 

































Figure 2. The incidence of AF in seven epidemiologic studies in general population. The data of 
those studies are given in Table 5 in the Appendix. Each study is presented with its 











2.2.2.3 Epidemiology of paroxysmal, persistent and permanent AF 
Based on the Framingham database the prevalence and incidence of chronic and transient 
AF has been assumed to be of the same order (Kannel et al. 1983). There also seems to be 
a common pattern of short episodes of AF to lengthen and a tendency of recurrent or 
paroxysmal AF to become persistent and chronic AF (Kopecky et al. 1987, Lévy et al. 
1999, Humphries et al. 2001, Kerr et al. 2005). 
 
The number or percentage of AF patients arriving for elective electrical cardioversion 
in a population-based study setting has not been documented before. In addition, the rate 
of progression from paroxysmal to persistent AF has been estimated to be 8.0% at 1 year 
(Lévy et al. 1999), but there are no published data regarding the progression rate from 
persistent AF treated with cardioversion to permanent AF. 
2.2.2.4 Conditions predisposing to AF in general population 
Ostrander et al. already documented higher prevalence of AF in citizens with increasing 
age and rheumatic heart disease (Ostrander et al. 1965). Practically all of the studies 
considering the prevalence and incidence of AF have also evaluated the predisposing 
factors or associated conditions to AF. The spectrum and quantity of predisposing 
conditions have very large variability in relation to the study period and the population 
studied. The most striking change in AF patients’ profile has been the proportion of 
patients with rheumatic valvular disease that has nearly disappeared in developed 
countries (Ostrander et al. 1965, Lévy et al. 1999, Fuster et al. 2006). 
 
At population level, age is the strongest independent risk factor for AF (Greenlee and 
Vidaillet 2005, Fuster et al. 2006). Quite constantly about 75% of AF patients are reported 
to be ≥ 65 years old and the mean age of AF patients is approximately 70 years (Go et al. 
2001, Majeed et al. 2001, Ruigómez et al. 2002, Fuster et al. 2006, Miyasaka et al. 2006). 
The odds ratio of the increased risk of AF for age has been estimated to be 1.05-1.11 per 
year or 2.1-2.2 per decade (Benjamin et al. 1994, Psaty et al. 1997, Stewart et al. 2001, 
Wilhelmsen et al. 2001, Frost et al. 2005). Increasing atrial fibrosis during aging is maybe 
the most important reason for the association between aging and AF (Allessie et al. 2002). 
 
Male sex predisposes to AF with an age-adjusted odds ratio of about 1.4-1.8 (Kannel et 
al. 1998, Stewart et al. 2001, Ruigómez et al. 2002, Miyasaka et al. 2006). However, 
because of the longer life expectancy in the female population, the number of male and 
female AF patients is about the same. The reason for the higher propensity to AF in males 
might be the greater stature and therefore larger atria of men and also their higher alcohol 
consumption (Greenlee and Vidaillet 2005). 
 
Great stature and especially obesity (BMI ≥ 30) is very strongly associated with 






al. 2006). This is of great importance, bearing in mind the increasing proportion of obese 
people in Western countries. Miyasaka et al. estimated in their paper that a 60% increase 
in age- and sex-adjusted risk of AF could be attributed to obesity. If this trend continues 
the number of AF patients in the United States could be as high as 15.9 million by 2050, 
accounting for about 3% of the population (Miyasaka et al. 2006). Although a favorable 
effect of weight loss on P-wave duration and P-wave dispersion has been shown there are 
no data documenting suppression of AF with weight loss (Duru et al. 2006). 
 
Hypertension is the background diagnosis that is most often associated with AF. With 
modern, strict criteria the prevalence of hypertension is 44% in European adults and 28% 
in North American adults (Wolf-Maier et al. 2003). The proportion of AF patients having 
diagnosed hypertension varies from 25% to 80% and the odds ratio for AF with a 
diagnosis of hypertension is 1.5 - 1.8 (Benjamin et al. 1998, Lévy et al. 1999, Humphries 
et al. 2001, Ruigómez et al. 2002, Go et al. 2001, Frost et al. 2005, Miyasaka et al. 2006, 
Murphy et al. 2007). Atrial remodeling caused by hypertension was determined as a 
prolongation of P-wave in signal-averaged ECG (SAECG) by Madu et al. and by Aytemir 
et al. showing that P-wave prolongation – a well-known indicator of the risk of AF – is 
strongly associated with hypertension. The P-wave duration was also associated with the 
severity of hypertension (Madu et al. 2001, Aytemir et al. 2005). Since those studies did 
not include echocardiographic data, it is not known whether the longer P-wave duration in 
hypertensive patients is a result of the established association between hypertension and 
left atrial enlargement (Vaziri et al. 1995). Indeed, it has been shown that treatment of 
hypertension – at least with ACE (angiotensin-converting enzyme) inhibitors – is 
associated with shortening of P-wave (Zaman et al. 2004). 
 
LVH measured by either echocardiography or ECG is a well-known risk factor of AF 
(Kannel et al. 1998, Stewart et al. 2001). LVH is both an indicator of stressed left 
ventricle, most often because of hypertension, and of LV diastolic dysfunction affecting 
atrial emptying and pressure. In the FHS, LVH in ECG was associated with a 3.0 - 3.8-
fold increased risk of AF (Kannel et al. 1998). 
 
Heart failure is both a cause and a consequence of AF, and it is diagnosed in 20-35% 
of AF patients (Kannel et al. 1998, Go et al. 2001, Ruigómez et al. 2002, Miyasaka et al. 
2006, Dagres et al. 2007). There is, however, some disagreement with echocardiographic 
findings, where AF patients seem to have well-preserved left ventricular (LV) systolic 
function. For example, in the FHS patients with and without AF had fractional shortenings 
of 37.1% and 38.6%, respectively (Kannel et al. 1998). In clinical practice it is likely that 
AF patients – because of older age – have more often diastolic dysfunction, which with 
high ventricular rate during AF might predispose to symptomatic heart failure without 
diminished LV systolic function. In the FHS, diagnosed heart failure was associated with a 
4.5- and 5.9-fold risk of AF in men and women, respectively (Kannel et al. 1998). Patients 
with severe heart failure have the highest reported incidence of AF. In a patient group 
referred for evaluation of heart transplantation new AF was diagnosed in 8.1% of patients 







There is no reliable estimation of the proportion of valvular heart disease in AF 
patients. In the FHS 24.7% of AF patients had mitral annular calcification compared to 
11.9% of patients without AF, but in the CHS valvular disease was diagnosed in only 3.8 
– 8.0% of AF patients (Psaty et al. 1997, Kannel et al. 1998). At present, valvular heart 
disease is seldom found as a causative factor for AF in clinical practice in the developed 
countries (Wilhelmsen et al. 2001, Fuster et al. 2006). 
2.2.2.5 Impact of AF in general population 
Heart failure has a dual association with AF, being both a cause and a consequence of AF. 
As mentioned earlier, heart failure is diagnosed in about 20% of AF patients, and in the 
presence of heart failure, development of AF is highly increased. In the Framingham 
material the dual roles of AF and heart failure were very convincingly documented, as it 
was found that in AF subjects the subsequent development of CHF was associated with 
increased mortality with a hazard ratio of 2.7 in men and 3.1 in women. Correspondingly, 
in patients with heart failure, development of AF was associated with a hazard ratio of 
mortality of 1.6 in men and 2.7 in women (Wang 2003). A good rate control has been the 
key means to avoid heart failure, since the published data have previously not proven any 
benefit on mortality from interventions to restore and maintain SR in either patients with 
normal or with depressed LV systolic function (Tuinenburg et al. 1999, Van Gelder et al. 
2002, Wyse et al. 2002, Roy et al. 2008). In the recently published ATHENA trial AF 
patients were treated with a new antiarrhythmic drug, dronedarone, and those randomised 
to the active drug benefited, with an increased likelihood of SR as well as a decreased 
number of cardiovascular deaths (Hohnloser et al. 2009). Those results might encourage 
intentions aimed at restoration and maintenance of SR with newer and safer methods. 
 
The increased risk of stroke in AF patients was first documented in the FHS, being 5.6 
times as frequent compared to the cohort without AF, while the risk of stroke in patients 
with rheumatic heart disease was 17.6-fold (Wolf et al. 1978). In the Mayo Clinic material 
1.3% of patients with lone AF had a stroke during a 15-year follow-up, which is similar to 
expected rates (Kopecky et al. 1987). A recent analysis of the same database revealed that 
this risk of stroke in lone AF patients continues to be the same as expected up to 25 years, 
but becomes significantly higher when the follow-up is extended to more than 30 years 
(Jahangir et al. 2007). On average, the rate of stroke among patients with non-valvular AF 
and without anticoagulation therapy is 5% per year, which is 2 to 7 times that of a 
comparable population without AF. The risk of stroke tends to be equal in patients with 
sustained and paroxysmal AF (Fuster et al. 2006, Hohnloser et al. 2007).  
 
Most studies assessing mortality in an AF population comparable to a population 
without AF have found an increased risk of all-cause death in AF patients. Mortality is 
approximately 1.5- to 2-fold with AF, and this excess mortality is seen among 






in new AF compared to an old diagnosis of the arrhythmia (Benjamin et al. 1998, Kannel 
et al. 1998, Lévy et al. 1999, Vidaillet et al. 2002, Fuster et al. 2006).  
2.2.3 Epidemiology of atrial fibrillation in acute myocardial infarction 
2.2.3.1 Prevalence of AF in AMI patients 
The mean age of AMI patients is around 70 years – with risk of AF, in addition to AMI – 
so the prevalence and incidence of AF is very high (Goldberg et al. 2004). The largest 
database on acute myocardial infarction (AMI), assessing the frequency and outcome of 
AF patients is from the Worcester Heart Attack Study. Since 1975, the group has collected 
a population-based database in Worcester, Massachusetts, USA, of residents who have 
been hospitalised and discharged with a diagnosis of AMI (Goldberg et al. 1990, Goldberg 
et al. 2004). In the 1970s and ’80s the proportion of AF patients during hospitalisations 
due to AMI was 16%, and AF was documented to be present on the first day of 
hospitalisation in 48% (Goldberg et al. 1990).  
 
The Cooperative Cardiovascular Project (CCP) is a nationwide register in the US 
including patients with a primary discharge diagnosis of AMI (Rathore et al. 2000). 
Focusing their analysis on patients ≥ 65 years of age, they found an AF prevalence of 22% 
in more than 100,000 AMI hospitalisations in the middle of the 1990s (Rathore et al. 
2000). Half of the patients were recorded as having AF on their admission ECG performed 
within 6 hours of arrival. The GRACE register collected data of acute coronary syndromes 
(ACS) from 14 countries in 1999-2003. From that database it was found that AF was seen 
during the index hospitalisation in 9% of all ACS cases and in 10% of AMI cases (Budaj 
et al. 2005). European and Scandinavian viewpoints are provided by the RIKS-HIA 
register, which includes coronary care units of a large number of Swedish hospitals 
(Stenestrand et al. 2005). Of the 82,000 AMI patients with first-time admission who were 
discharged alive between 1995 and 2002 8% had AF on the discharge ECG (Stenestrand et 
al. 2005). 
 
Another perspective is given by prospective, randomised drug trials. Three large-scale 
trials evaluating different therapies among patients with ST-elevation AMI (STEMI) have 
also published the prevalence of AF. The GUSTO-I, GUSTO-III and GISSI-3 trials had 
AF prevalences at entry of 2.5%, 0.8% and 1.1%, respectively (Crenshaw et al. 1997, 
Wong et al. 2000, Pizzetti et al. 2001). The TRACE study investigated an ACEi, 
trandolapril, and the VALIANT study an angiotensin receptor blocker (ARB), valsartan, in 
treatment of patients with AMI and signs of LV dysfunction (Pedersen et al. 1999a, Køber 
et al. 2006). In the TRACE database 3.9% and in the VALIANT-trial 2.3% of the patients 
had had documented and diagnosed pre-existent AF before entry to the study (Pedersen et 
al. 1999a, Køber et al. 2006). However, in the VALIANT study patients with AF during 






the prevalence of previous AF (Køber et al. 2006). On the other hand, the total proportion 
of AF patients (14.7%) was of about the same order as in the TRACE database (21%) 
(Pedersen et al. 1999a, Køber et al. 2006). DIAMOND-MI is the only trial studying an 
antiarrhythmic drug in AMI patients with LV dysfunction, and 7.6% had AF at entry 
(Køber et al. 2000).  
 
Prospective, randomised drug trials studies can be criticised because of selection, and 
comparisons between the studies are difficult to perform because of different inclusion and 
exclusion criteria. On the other hand, the data provided by drug studies are in principle 
more exact compared to register studies, and when the AF data are documented, the 
numbers of previous AF as well as newly developed AF are mainly presented. 
2.2.3.2 Incidence of AF in AMI patients 
Most AMI studies only have information about the proportion of AF patients during the 
study period. There are, however, some studies that differentiate between AF as a pre-
existing property or a condition that has developed during or after AMI. In the Worcester 
Heart Attack Study and CCP registry the amount of new AF could be estimated from the 
proportion of patients, who had not had AF at the first hospital recording. From 1975 to 
1986 in Worcester, 8.3% of patients with AMI developed new AF during the 
hospitalisation, about 40% developed AF within three days after admission, and 60% 
developed AF thereafter (Goldberg et al. 1990). In the CCP registry in patients ≥ 65 years 
old 11.3% of patients developed AF during AMI hospitalisation (Rathore et al. 2000). 
 
Clinical drug trials have perhaps the most precise analysis of cardiovascular events 
occurring in the populations studied. In the GUSTO-I and GISSI-3 trials of patients with 
STEMI, 7.9% and 7.8% developed AF during hospitalisation, respectively (Crenshaw et 
al. 1997, Pizzetti et al. 2001). Pizzetti et al. also reported a significant 24% reduction in 
the incidence of AF in patients randomised to lisinopril + nitrates compared to the 
placebo-allocated group (Pizzetti et al. 2001). In the GUSTO-III trial a new AF during 
hospitalisation or within 30 days of enrolment was documented in 6.5% of patients (Wong 
et al. 2000).  
 
AMI-trials evaluating patients with signs of LV dysfunction have the highest 
proportion of patients with new AF. In the TRACE database the percentage of a new AF 
was 17.1% during hospitalisation (Pedersen et al. 1999a). In the main TRACE trial, of 
those who had SR at baseline 2.8% allocated to trandolapril and 5.3% allocated to placebo 
developed AF during the up to 4-year follow-up; p-value < 0.01. This was the first study 
to demonstrate that blocking the renin-angiotensin-aldosterone system (RAAS) reduces 
significantly the incidence of AF (Pedersen et al. 1999b). In the DIAMOND-MI study 
long-term treatment with dofetilide was determined on mortality and morbidity in 
survivors of AMI and LV dysfunction (Køber et al. 2000). Among patients with SR at 






compared to 2.0% in the placebo group, but this difference was non-significant (Køber et 
al. 2000). 
2.2.3.3 Conditions predisposing to AF in AMI  
As in the general population, age is the strongest predictor for AF in AMI patients as well. 
In the Worcester Heart Attack Study the mean age of AMI patients with AF was 73.0 
years, compared to 65.5 years in patients without AF (Goldberg et al. 1990). Based on the 
same material, the mean age of patients hospitalised with AMI is continuously increasing, 
emphasising the role of AF in this population (Goldberg et al. 2002, Goldberg et al. 2004). 
The finding of AF patients being older among AMI populations has been repeated in all 
analyses of this kind; OR for having AF for a one-year increase of age is about 1.06 and 
OR for age more than 70 years is about 2.8 (Pizzetti et al. 2001, Kinjo et al. 2003). 
Although female gender seems to be associated with higher frequency of AF during AMI, 
this is most probably the result of female AMI patients being also significantly older than 
men (Goldberg et al. 1990, Wong et al. 2000, Goldberg et al. 2002).  
 
More severe clinical status during AMI reflects hemodynamic load and is associated 
with higher occurrence of AF. Both higher systolic and diastolic blood pressure at baseline 
as well as higher heart rate have increased the risk of AF (Crenshaw et al. 1997, Wong et 
al. 2000, Pizzetti et al. 2001, Køber et al. 2006). Severity of the clinical status and 
association with AF have been observed in the presence of congestive heart failure, higher 
Killip class, cardiogenic shock, anterior MI location and Q-wave AMI and ventricular 
arrhythmias (Goldberg et al. 1990, Behar et al. 1992, Crenshaw et al. 1997, Eldar et al. 
1998, Rathore et al. 2000, Pizzetti et al. 2001, Goldberg et al. 2002, Kinjo et al. 2003, 
Køber et al. 2006). The amount of myocardial necrosis assessed as higher a amount of 
myocardial enzymes or lower LV ejection fraction have also been associated with 
increased the risk of AF (Behar et al. 1992, Crenshaw et al. 1997, Pedersen et al. 1999a, 
Køber et al. 2006). As a sign of atrial electrical remodeling or electrical predisposition to 
AF, P-wave duration measured with SAECG in a very early period of AMI was a useful 
tool in predicting the development of AF (Rosiak et al. 2003). 
2.2.3.4 Impact of AF on morbidity and mortality in AMI 
Since AF is associated with various baseline diagnoses and signs of more severe 
cardiovascular state, the independent prognostic significance of AF is not straightforward. 
In addition, in most analyses the impact of AF has been dissimilar when patients with a 
pre-existing AF and patients with a newly developed AF have been compared. Therefore, 
this kind of analysis has to be performed separately in patient groups comparing patients 
with “old AF”, “new AF” and “no-AF”, regardless of the determination of these different 







In the Worcester Heart Attack Study “early AF” had a non-adjusted hazard ratio (HR) 
of 1.66 for total mortality, but in multivariate analysis only a non-significant trend with 
risk of 1.04 HR was reported (Goldberg et al. 1990). On the other hand, in the CCP and in 
the TRACE, GUSTO-III and VALIANT trials previous AF was associated with higher 
mortality rate (Pedersen et al. 1999a, Rathore et al. 2000, Wong et al. 2002, Køber et al. 
2006). An interesting finding is that pre-existent AF seems to increase long-term mortality 
with no association with in-hospital mortality (Pedersen et al. 1999a, Rathore et al. 2000, 
Wong et al. 2002). A history of chronic AF decreased the survival rate, while patients with 
paroxysmal AF had the same survival rate as patients without AF (Wong et al. 2002).  
 
Compared to pre-existent AF, the impact of newly developed AF on the risk of death is 
much more widely recognised, and the HRs with new AF have been higher. The adjusted 
hazard ratios for death in AMI patients who develop AF has been estimated to be from 1.3 
to 3.0, including both in-hospital and long-term mortality (Sakata et al. 1997, Rathore et 
al. 2000, Pizzetti et al. 2001). Sakata et al. also analysed separately patients who 
developed AF within 24 hours of onset of AMI and patients who developed AF later 
during the hospitalisation. Compared to the patients without AF, adjusted OR for death for 
early AF was 2.5 and that for later AF 3.7 (Sakata et al. 1997). 
 
Besides the prognosis, AF is associated with a more unfortunate course of AMI, stroke 
being the most worrying complication. In general AMI populations, the CCP, Worcester 
Heart Attack Study and the GRACE registry have recorded a higher rate of stroke in AF 
patients. For example, in the GRACE registry AF had an adjusted OR of 2.5 for in-
hospital stroke (Rathore et al. 2000, Spencer et al. 2003, Budaj et al. 2005). In the 
Worcester Heart Attack Study 32% of the patients with AMI and stroke had AF, compared 
to 15% of AF in the patients without stroke (Spencer et al. 2003). The risk of stroke in 
clinical trials has been estimated to be about two-fold compared to the patients without AF 
(Crenshaw et al. 1997, Wong et al. 2000, Køber et al. 2006).  
 
AF is a very common arrhythmia seen during AMI. The clear relationship between AF 
and poorer outcome can be explained by diminished cardiac output and higher rate of 
congestive heart failure, and the risk of stroke by the absence of atrial systole during the 
arrhythmia. AF is not only a risk for complications but also a strong marker of more 
advanced cardiovascular disease, and the relations between AF and different endpoints 
have been extensively examined. However, there have been no analyses where AF has 
been included as a time-dependent co-variate to allow a logical demonstration of a 






2.3 Atrial remodeling 
2.3.1 Concept of atrial remodeling 
It is important to understand the term “wavelength” in AF. During systole electrical 
activity passes over the cardiac myocardium as an electrical wavelet, but in AF there are 
many of those wavelets causing rapid irregular electrical activity in the atria. To put it 
simply, wavelength (λ) is the distance between repeating units of propagating waves of a 
given frequency, and can be interpreted as the result of the conduction velocity divided by 
the frequency (λ = CV / F); or the velocity multiplied with the effective refractory period 
(ERP) (λ = CV x ERP). In practice, three components of atrial properties are involved in 
and contribute to the stability of AF: conduction velocity, effective refractory period and 
atrial size (Allessie et al. 2002, Nattel 2002). When the wavelength is short, it allows more 
re-entering wavelets to exist in the available surface of the atria, and vice versa: if the 
available surface area of the atria is large, there is room for more wavelets. Slowed 
conduction velocity and shortened ERP – and hence decreased wavelength – allows 
wavelets to propagate with shorter distance from each other (Allessie et al. 2002, Nattel 
2002). Therefore, in order to stabilise AF at least one of these is needed: atrial 
enlargement, shortening of ERP or a decrease of conduction velocity. This theory has been 
proven in both computer models and animal, in addition to human experiments (Moe and 
Abildskov 1959, Moe et al. 1964, Cox et al. 1991).  
 
AF is very uncommon during the first decades after birth but extremely common in the 
elderly. If AF is diagnosed in an adolescent, most often some kind of hereditary syndrome 
– such as Brugada syndrome or hereditary cardiomyopathy – is diagnosed (Junttila et al. 
2004, Pethig et al. 2005), and when AF develops in advanced age, the heart and the atria 
have for decades been exposed to hypertension, for example. When a cohort of new AF 
patients is examined there is always a high probability of previous asymptomatic AF 
episodes and therefore atrial remodeling caused by AF itself (Frykman et al. 2001, Israel 
et al. 2004). There is nevertheless evidence that AF patients might have some 
dissimilarity, especially in atrial electrical properties predisposing to AF. A Belgian cohort 
of subjects (2,200 patients, age > 40 years) in SR at baseline was re-evaluated after more 
than 10 years. The 10-year incidence of AF was 4.38 per 1,000 person years, and longer 
and notched or deflected P-waves at baseline were independent risk markers for 
development of AF (De Bacquer et al. 2007). However, AF patients also had significantly 
more often hypertension and “ischemic ECG changes”, possibly reflecting LV strain, and 
thus the development of AF as well as the P-wave differences might have been the product 







In this concept atrial remodeling is considered as any change – temporary or persistent 
– in appearance, layout, or properties of the atria occurring because of a heart disease 
(cardiovascular remodeling), or because of atrial tachycardia or AF (AF remodeling). The 
third “mechanism” that alters the atrial myocardium and causes atrial remodeling by 
increasing atrial fibrosis – aging – is not considered in this context. Atrial remodeling is a 
multifactorial phenomenon, and its mechanisms and elements are overlapping. Atrial 
remodeling is discussed separately as electrical, functional (contractile) and structural 
remodeling (Allessie et al. 2002). 
2.3.2 Where does remodeling come from? 
The principal mechanisms for atrial remodeling are atrial tachycardia and atrial stretch 
(Savelieva and Camm 2004). Experimental atrial tachypacing and congestive heart failure 
(CHF) are the two principal investigational models; recently also hypertension models 
have been introduced to evaluate the associations between an extra-atrial disease and AF 
(Allessie et al. 2002, Choisy et al. 2007, Nattel et al. 2008). 
 
It has for a long time been observed that patients with paroxysmal AF have a tendency 
to develop persistent AF, and that restoration and maintenance of SR depends on the 
duration of AF (Viko et al. 1923, Parkinson and Campbell 1929, Bjerkelund and Orning 
1968, Kopecky et al. 1987). These findings suggest that AF is a self-perpetuating 
phenomenon. In 1995 two separate groups established the association between atrial 
tachycardia and changes – remodeling – in the atria predisposing to AF. In a canine model 
with continuous rapid atrial pacing (RAP) (6 weeks, 400 bpm), shortening of ERP and 
atrial fibrillation cycle length (AFCL) plus increased inducibility of AF was observed 
(Morillo et al. 1995). These results were confirmed by Wijffels et al. in an ovine model 
with artificially maintained AF (Wijffels et al. 1995). In addition to these 
electrophysiological changes, Morillo et al. also found a marked increase in atrial volume 
as well as an increase in the number and size of the mitochondria documented by electron 
microscopy (Morillo et al. 1995). Wijffels et al. also found that the normal physiological 
rate adaptation of the refractory period (longer ERP at slower heart rate) was either 
attenuated or even reversed (Wijffels et al. 1995). It has to be noted that ventricular rate 
was not controlled in either of these studies, and there might also have been CHF-induced 
atrial remodeling due to long-lasting high ventricular rate. Soon after these animal 
experiments atrial electrical remodeling with induced AF and also in AF patients after 
electrical CV was documented in man (Daoud et al. 1996, Pandozi et al. 1998). 
 
The clinical evidence of an association between CHF, hypertension and AF is vast 
(Benjamin et al. 1994, Kannel et al. 1998, Healey and Connolly 2003, Savelieva and 
Camm 2004, Fuster et al. 2006). Despite this clear clinical implication, the mechanisms of 
these associations have just recently been enlightened. The first CHF model experiment 
was performed by Professor Nattel’s group in Canada. They had three groups of dogs: one 






group with RAP with AV-node ablation (Li et al. 1999). Both tachypaced groups 
developed a significantly longer duration of induced AF, but CHF dogs also had markedly 
increased LV mass and atrial fibrosis compared to the RAP group. In electrophysiological 
measurements RAP dogs had decreased ERP, wavelength and AF current length, while all 
these variables were unchanged in CHF dogs. As a result of fibrotic atria, CHF dogs had 
higher heterogeneity of conduction and areas of slow conduction in atrial tissue (Li et al. 
1999). In a study on human subjects, Sanders et al. had a group of patients with 
documented CHF during electrophysiological procedure. They established not an 
unchanged, but even a lengthened ERP, and like Li et al., impaired atrial conduction and 
increased inducibility of AF – even in the absence of prior AF (Sanders et al. 2003a). The 
same remodeling changes (slowed conduction, increase in the electrical heterogeneity and 
atrial collagen content plus tendency to AF) were noted by Kistler et al. in an ovine 
hypertension model (Kistler et al. 2006). The main mechanism for atrial remodeling in all 
of these studies is assumed to be atrial stretch (Li et al. 1999, Sanders et al. 2003a, Kistler 
et al. 2006, Kirchhof and Schotten 2006). 
2.3.3 Electrical atrial remodeling 
In AF atrial cells are very rapidly overloaded with Ca2+-ions that are cytotoxic (Nattel et 
al. 2008). This deleterious phenomenon is attenuated by reduced Ca2+ influx via functional 
inactivation of L-type Ca-channels (ICaL) during phase 2 of action potential, but this also 
causes a marked decrease in atrial action potential duration (APD). When tachycardia is 
prolonged Ca-channel protein formation is downregulated, and also protein 
dephosphorylation and breakdown take place, proceeding with the process of Ca2+ influx 
reduction (Nattel et al. 2008). Of the outward potassium channels Ito is also downregulated 
during the first hours of tachycardia. Downregulation of Ito is seen especially in patients 
with chronic AF, but the functional importance of this is unclear (Van Wagoner 2003, 
Nattel et al. 2007). The results regarding other outward potassium channels are 
conflicting, but it seems that atrial-specific IKur is reduced in human chronic AF (Van 
Wagoner 2003, Nattel et al. 2007). 
 
AF patients without structural heart disease have atypical P-waves in standard 12-lead 
ECG (Robitaille and Phillips 1967). Lengthening of the P-wave has thereafter been 
measured and confirmed from body surface with standard 12-lead ECG, SAECG and 
MCG in numerous studies (Fukunami et al. 1991, Guidera and Steinberg 1993, Dilaveris 
et al. 1998, Winklmaier et al. 1998, Darbar et al. 2002). However, APD shortening does 
not cause the prolongation of the P-wave, and there have to be some other mechanisms. 
There is controversy about the modulation of INa, the major contributor of phase 0 of 
action potential, but it seems that the activation of INa is reduced, at least in man, in 
chronic AF, thus slowing atrial conduction (Van Wagoner 2004, Nattel et al. 2007). 
Redistribution or functional or quantitative changes of connexins – proteins that promote 
activation from cell to cell – could be the other tachycardia-related alteration explaining 






the role of connexins in electrical remodeling (Nattel et al. 2007, Duffy and Wit 2008). 
Longer RAP was needed to develop reduced conduction velocity and increased 
heterogeneity than ERP shortening. However, ventricular rate was not controlled in this 
canine model either, and the impact of the development of CHF cannot be excluded 
(Gaspo et al. 1997). The slowed as well as distorted intra- and interatrial conduction has 
also been observed in AF patients (Xia et al. 2004). 
 
CHF and hypertension have a very different effect on atrial electrophysiology 
compared to RAP or AF (Li et al. 1999). The reduced activity of reporalisating outward 
potassium channels is the main alteration in ion-channel function that is associated with 
prolonged repolarisation and increased APD (Nattel et al. 2007). Contrary to RAP or AF, 
CHF therefore induces prolonged ERP that is recognized in both animal experiments and 
in man (Shinagawa et al. 2002a, Sanders et al. 2003a). Shinagawa et al. also presented that 
shortening of lengthened ERP could be induced in CHF dogs with RAP (Shinagawa et al. 
2002a). Other arrhythmia-predisposing electrophysiological changes in CHF are increased 
Na+-Ca2+-exchanger (NCX) activity increasing spontaneous activity and changes in 
connexin function contributing to slowed conduction (Nattel et al. 2007). Prolongation of 
P-wave in CHF has been documented both in animal experiments and in patients with 
CHF (Sanders et al. 2003a, Sakabe et al. 2004). 
 
In hypertension models, atrial electrical remodeling has been similar to the CHF 
models. In a hypertensive rat model and in the already mentioned hypertensive ovine 
model atrial ERP was not changed, but atrial tachycardia was more susceptible (Kistler et 
al. 2006, Choisy et al. 2007). Hypertensive sheep also had significantly reduced 
conduction velocity in the atria compared to the control animals (Kistler et al. 2006). 
2.3.4 Functional atrial remodeling 
Heart muscle cell contraction is started via Ca2+ influx and promoted by Ca2+ release from 
the intracellular sarcoplasmic reticulum. Calcium overload and downregulation of ICaL is 
the major ion channel alteration and origin of electrical remodeling that also causes 
tachycardia-induced contractile dysfunction (Allessie et al. 2002). Therefore it can be said 
that not only does “AF beget AF” but also “remodeling begets remodeling”. In 
experimental models, even five minutes of AF decreased atrial contractility by 55%, and 
five days of AF abolished atrial contractility nearly completely (Schotten et al. 2003). The 
vital role of Ca2+ and ICaL was also shown when selective blocking of ICaL almost 
completely preserved atrial contractility (Schotten et al. 2003). CHF had a more marked 
contribution to atrial function compared to RAP in a dog AF model (Shi et al. 2001). The 
diminished atrial function in AF patients has been known for decades; more recently it has 
also been documented with echocardiography (Logan et al. 1965, Manning et al. 1989). 
 
Reduced atrial pump function increases blood volume in the atria, causes atrial 






contraction disturbed, but also atrial relaxation is distorted in AF (White et al. 1982, 
Abhayaratna et al. 2006). An important finding linking atrial functional depression (and 
raised atrial pressure) with atrial electrophysiology has been that both CHF and increased 
intra-atrial pressure increase spontaneous electrical activity from pulmonary veins 
(Fenelon et al. 2003, Kalifa et al. 2003). 
2.3.5 Structural atrial remodeling 
AF decreases atrial pump function, but AF also acutely decreases atrial distensibility, with 
only a small increase (about 10%) in atrial diameter (White et al. 1982). This leads to a 
rapid increase of atrial pressure and distension, and because of the thin muscular layer of 
the atria, the atria become enlarged after a while (White et al. 1982, Morillo et al. 1995). 
Indeed, it has been documented that left atrial dimensions increase over time in AF 
patients without any heart diseases; and both RAP and CHF increase atrial dimensions, 
but in the CHF model atrial enlargement has been more outstanding compared to the atrial 
tachypacing model (Sanfilippo et al. 1990, Shi et al. 2001). 
 
Microscopic structural remodeling because of tachycardia is detected as swollen 
myocardial cells, accumulation of glycogen, myolysis, mitochondrial enlargement and 
changes in the shape and fragmentation of the sarcoplasmic reticulum (Morillo et al. 1995, 
Ausma et al. 1997, Schotten et al. 2001, Allessie et al. 2002). In lone AF patients 
increased collagen deposition has been documented in atrial tissue specimens, and AF 
patients with mitral valve disease had more marked collagen expression compared to AF 
patients without this valve disease (Frustaci et al. 1997, Boldt et al. 2004). However, it 
seems that the causal association between tachycardia and atrial fibrosis is not very clear, 
and in animal models increased fibrosis has not been documented with even up to 20 
weeks of tachycardia (Ausma et al. 1997, Li et al. 1999, Ausma et al. 2001, Burstein and 
Nattel 2008). These animal models may have been too short in duration, because there is 
nevertheless an association between tachycardia and upregulation of fibroblast function 
(Burstein et al. 2007). The mechanisms of irreversible changes leading to atrial cell death 
and cellular apoptosis also seem to be dependent on stretch, because the tachycardia models 
have not induced apoptosis, which is seen in the atria of older patients and/or patients with 
associated heart diseases (Dispersyn et al. 1999, Allessie et al. 2002).  
 
Atrial tissue specimens of AF patients have constantly revealed atrial fibrosis that is 
more pronounced with structural heart diseases (Frustaci et al. 1997, Boldt et al. 2004). 
Compared to the animal models, AF has often been long-standing before a biopsy in AF 
patients, predisposing the atria to both long-standing tachycardia and increased atrial 
pressure. An unequivocal difference exists when animal CHF models and tachycardia 
models are compared regarding fibrous formation. Li et al. clearly demonstrated “atrial 
remodeling of a different sort” having both CHF and tachycardia models in an experiment 
where CHF strongly promoted fibrosis that was not seen in atrial tachycardia model dogs 
(Li et al. 1999). The main mediators behind atrial fibrosis are increased activation of 
angiotensin-II (Ang-II) and transforming growth factor-1 (TGF-1) that are activated 
within hours; increased atrial fibrosis is already detectable 24 hours after the onset of 
ventricular tachypacing (Cardin et al. 2003, Hanna et al. 2004, Burstein and Nattel 2008, 
Nattel et al. 2008). Atrial fibrosis is prominent in CHF models, and substantially more 
fibrosis as well as higher Ang-II concentrations are seen in the atria than in the ventricles 
during ventricular tachypacing (Li et al. 1999, Cardin et al. 2003, Hanna et al. 2004).  
 
In hypertension animal models increased atrial fibrosis is the most striking finding, 
corresponding to structural remodeling seen in the CHF models, and it is observed in 
hypertensive rats already at 3 months of age (Kistler et al. 2006, Choisy et al. 2007). Left 
atrial dimension has also been increased in hypertensive animals (Kistler et al. 2006). 
Fibrosis causes conduction block areas in the atria that are a source of spatial 
heterogeneity in atrial conduction, making re-entrant circuits possible (Allessie et al. 2002, 
Nattel 2002, Burstein and Nattel 2008). By decreasing atrial conduction velocity fibrosis 
shortens the wavelength and increases the perpetuation of AF. Diminishment of atrial 
pump function is enhanced by myolysis and fibrous formation, and thus it could again be 
said that “remodeling is causing remodeling” (Allessie et al. 2002, Burstein and Nattel 
2008). The associations between different forms of atrial remodeling and AF are proposed 
in Figure 3. 
 
 
Figure 3. Vicious circles of atrial electrical, functional and structural remodeling and their 
relations to atrial fibrillation. 












2.3.6 Reverse atrial remodeling 
Atrial remodeling is a self-perpetuating event making AF more susceptible and more 
persistent; “AF begets AF”. Fortunately the atria have a spontaneous tendency to cease the 
fibrillating arrhythmia, at least when arrhythmia is of short duration, and most often AF 
can be stopped and SR restored with electrical or pharmacological cardioversion. Reverse 
remodeling during SR is essential for the atria to avoid new episodes of AF. 
 
Logan et al. not only documented functional remodeling, but they also recognised 
reversal of atrial function (Logan et al. 1965). They showed that a patient who had had AF 
for 8 weeks had no evidence of atrial contraction immediately after electrical 
cardioversion, but developed a detectable atrial a-wave twenty minutes later in cardiac 
catheterisation (Logan et al. 1965). Manning et al. documented with echocardiography that 
recovery of left atrial mechanical function may take up to three months, and in their 
extended study they found that the time course of recovery is related to the duration of AF 
before cardioversion (Manning et al. 1989, Manning et al. 1994). In fact, atrial mechanical 
function is even diminished immediately after cardioversion of persistent AF compared to 
the time before cardioversion, and thrombus formation in appendices may be enhanced 
during the first days after cardioversion (Grimm et al. 1993, Khan 2003, Sanders et al. 
2003b).  
 
Reversal of atrial electrical remodeling was already documented by Wijffels et al. in 
their classical work (Wijffels et al. 1995). In goats that had maintained AF 2 to 4 weeks, 
they noticed that ERP shortening, AF interval and length of induced AF episodes started 
to normalise after 6 hours of SR, and were improved at 24 hours, but complete reversal 
was not seen until one week after SR had been restored (Wijffels et al. 1995). In man, 
Daoud et al. found a significant shortening of atrial ERP during a mean of 7 minutes of 
pacing-induced AF (Daoud et al. 1996). ERP started to recover immediately when SR was 
restored and was entirely recovered in 8 minutes. They also found – implicating reverse 
atrial electrical remodeling – that the subsequent episodes of AF shortened as the elapsed 
time after conversion of AF was increased (Daoud et al. 1996). After cardioversion AF 
patients had significantly shorter ERP and prolonged atrial conduction time. After the four 
days of follow-up ERP was increased to similar level as in the control group, but atrial 
conduction times remained longer (Yu et al. 1999). Manios et al. had an 
electrophysiological study with similar findings as Yu et al., but they had a longer (one 
month vs. four days) follow-up time (Manios et al. 2000). They showed that prolongation 
of P-wave exhibited slower resolution, being normal not until one month after conversion 
to SR, implicating the same slower improvement in conduction times as documented by 
Yu et al. (Manios et al. 2000). The shortening of P-wave during SR after cardioversion is 
well established both with 12-lead ECG and SAECG, and patients with longer duration of 
AF before cardioversion had significantly smaller shortening of P-wave (Nishino et al. 
2000, Sato et al. 2001, Chalfoun et al. 2007). Nishino et al. documented P-wave 







After conversion to sinus rhythm the atria have a propensity to get smaller, and this is 
well established in both man and animal experiments (Manning et al. 1994, Mattioli et al. 
2000, Shinagawa et al. 2002b, Cha et al. 2004). There are no human data regarding 
microscopically assessed reverse atrial structural remodeling. Ausma et al. documented 
structural remodeling (myolysis) 4 months after restored SR in goats that had maintained 
AF for 4 months before a CV (Ausma et al. 2003). In a dog CHF model one month after 
cessation of tachypacing structural remodeling – assessed as atrial fibrosis – did not show 
a return toward control values (Cha et al. 2004). This is most probably the reason for the 
higher susceptibility of AF that is seen after a reasonable duration after CV of long-lasting 
AF, despite full hemodynamic and electrophysiological recovery (Allessie et al. 2002, Cha 
et al. 2004).  
2.3.7 Atrial remodeling in acute myocardial infarction  
In acute myocardial infarction the atria are confronted with increased sympathetic activity, 
atrial stretch and pressure, and possibly direct ischemia as well. Increased sympathetic 
activity predisposes to both atrial and ventricular arrhythmias, hence depressing normal 
cardiac function and increasing chamber pressures (Chen et al. 2004, Nattel et al. 2007). 
Furthermore, increased stretch and pressure cause atrial electrical, functional and 
structural remodeling, as observed (Chen et al. 2004, Nattel et al. 2007). 
 
Direct myocardial ischemia decreases delayed-rectifier potassium currents (IKr and 
IKs), ICaL as well as INa and resting potential (Nattel and Carlsson 2006, Nattel et al. 2007). 
As a consequence of these alterations, the myocardium is predisposed to increased 
spontaneous activation and slowed conduction (Nattel and Carlsson 2006, Nattel et al. 
2007). These results are, however, from models where ventricular heart tissue was 
examined, and thus might not be completely applicable in atrial tissue. Direct ischemia of 
the sinus node may cause bradycardia, enhancing the possibility of spontaneous 
arrhythmias as well as AF (Sakata et al. 1997). Later on, during the course of AMI, both 
atrial scarring because of atrial infarction and especially left ventricular dysfunction that 
develops may cause atrial remodeling resembling the stretch-induced, CHF-associated 
remodeling predisposing to AF (Nattel et al. 2007).  
2.3.8 What happens in the atria during AF? Remodeling in real life 
At the beginning of tachycardia atrial cells are overloaded with Ca2+-ions. This is 
associated with a short-lasting increase in atrial contractility measured after 20 seconds of 
atrial tachypacing (Schotten et al. 2003). However, after five minutes of tachypacing atrial 
contractility is markedly decreased, and after five days of AF atrial contractility has nearly 
disappeared, atrial functional remodeling being complete (Schotten et al. 2003). In man, 
10 - 15 minutes of AF was not enough to decrease left atrial appendage emptying velocity, 






al. 1999). In addition, 14% of patients with AF symptoms for less than three days had a 
left atrial appendage thrombus, indicating that atrial function is early disturbed during AF 
(Stoddard et al. 1995). Decreased contractility causes increased atrial pressure and 
dilatation seen already three days after initiation of AF (White et al. 1982, Schotten et al. 
2004).  
 
Atrial electrical remodeling also starts very rapidly, but it seems that 30 seconds is not 
enough for electrical remodeling in man (Vardas et al. 2001). However, shortening of 
APD and ERP is measurable within less than 10 minutes when subjected to AF (Daoud et 
al. 1996, Yu et al. 1998). Shortening and loss of rate dependence of APD is complete 
during the first days of AF, but it takes an additional 1 - 2 weeks until AF becomes 
persistent, and secondary remodeling mechanisms are needed for this evolution (Wijffels 
et al. 1997, Goette et al. 1996, Allessie et al. 2002, Kumagai et al. 2003).  
 
When AF lasts for a week atrial changes resembling embryonic development (re-
expression of fetal proteins) are initiated (Ausma et al. 2001, Allessie et al. 2002). Cell 
swelling and myolysis are also noted, and these are complete in about 8 weeks (Ausma et 
al. 2001, Allessie et al. 2002). Despite the clearly evident myolysis and cell death 
increased atrial fibrosis is not detectable even after four months in AF models, yet 
practically all human studies have revealed increased atrial fibrosis in AF patients 
(Frustaci et al. 1997, Ausma et al. 2001, Allessie et al. 2002, Boldt et al. 2004, Burstein 
and Nattel 2008). As noted, atrial tachycardia promotes increased fibroblast function in a 
cell experiment, but it is not known whether a longer duration of AF might also amplify 
fibrous formation in man (Burstein et al. 2007). However, in clinical practice 
approximately 70% of individuals with AF are between 65 and 85 years of age, and about 
90% of AF patients have a cardiovascular background diagnosis, most often hypertension 
(Furberg et al. 1994, Feinberg et al. 1995). Therefore, in real life most AF patients have a 
substrate for AF equal to that seen in CHF or hypertension models, predisposing to AF, 
and AF-promoted remodeling seen thereafter (Anyukhovsky et al. 2005, Kistler et al. 
2004, Kistler et al. 2006).  
 
2.4 The renin-angiotensin-aldosterone system and AF 
2.4.1 RAA system and atria 
The renin-angiotensin-aldosterone system (RAAS) has a pivotal role in the regulation of 
cardiovascular function (Felmeden and Lip 2000, Colucci and Braunwald 2005, 
Schmieder et al. 2007). Figure 4 shows a simplified overview of the RAAS cascade. The 
main effect of RAAS is mediated by the active endproduct angiotensin II (AngII) via 
specific cell surface proteins, angiotensin II-receptors, and by direct stimulation of AngII 
for aldosterone excretion from the adrenal cortex (Colucci and Braunwald 2005, 
Schmieder et al. 2007). Activation of AngII type 1 receptors (AT1) by AngII causes 
vasoconstriction, endorses cell proliferation of fibroblasts, causes myocardial hypertrophy, 
increases sympathetic nerve activity and promotes inflammation (Felmeden and Lip 2000, 
Boos and Lip 2005, Colucci and Braunwald 2005, Schmieder et al. 2007). Activation of 
AngII type 2 receptors (AT2) has antagonism on the effects of AT1, causing for example 
vasodilatation and having antiproliferative effects on fibroblasts (Felmeden and Lip 2000, 
Schmieder et al. 2007). With a particular emphasis on atria, AngII via AT1 shortens atrial 
action potential, induces after-depolarisations in pulmonary vein tissue, promotes 
apoptosis and cell death and causes marked atrial dilation with increased focal fibrosis 
(Boos and Lip 2005, Chen et al. 2006, Zankov et al. 2006, Burstein and Nattel 2008). 
RAAS is activated in congestive heart failure and by increased sympathetic activity 
(Colucci et al. 2005). RAAS is also activated by AF itself; AF increases ACE and AngII 
in atrial tissue, and thereby RAAS and AF act like a self-perpetuating vicious circle 







Figure 4. Renin-angiotensin-aldosterone system. The main regulators of the system are shown 
in black, and the medications that suppress the system are shown in red.  
ACE – angiotensin converting enzyme, AT1 – Angiotensin II type 1-receptor, ARB – 






2.4.2 Suppression of the RAA system and AF – experimental data 
2.4.2.1 Animal studies 
In a canine model Nakashima et al. observed a significant shortening of atrial ERP 30 
minutes after commencing of atrial tachypacing maintained for 180 minutes. After 
cessation of pacing the changes were corrected in 10 minutes (Nakashima et al. 2000). 
Infusion of AngII significantly accentuated the ERP shortening. When the animals got an 
infusion of either an angiotensin receptor blocker (ARB), candesartan, or an angiotensin-
converting enzyme inhibitor (ACEi), captopril, started before tachypacing, shortening of 
ERP was completely inhibited (Nakashima et al. 2000). In a comparable experimental 
arrangement a positive effect was not attained with the ACE inhibitor enalapril either on 
shortening of ERP or inducibility of AF when rapid atrial pacing was continued for 7 days 
and ventricular rate was controlled by AV ablation (Shinagawa et al. 2002c). 
 
AngII increases the influx of Ca2+-ions into myocardial cells, modulates ion channels 
of cell surface and causes shortening of ERP in both atrial and pulmonary vein tissue. This 
shortening of ERP is attenuated with RAAS-inhibiting drugs (Goette et al. 2004, Zankov 
et al. 2006, Chen et al. 2006). Besides the actions via RAAS, those drugs have direct, 
angiotensin-independent properties on ion channels with a small antiarrhythmic effect 
(Ehrlich et al. 2006). However, as noted, those direct antiarrhythmic effects are modest 
and may have a role in intact atria with normal action potential duration, but are not seen 
when atria are exposed to a rapid rhythm even for some days (Shinagawa et al. 2002c). 
 
In their model Kumagai et al. investigated the effect of rapid atrial pacing continued 
for five weeks without AV ablation and hence without controlled ventricular rate 
(Kumagai et al. 2003). Shortening of ERP was again noted with no effect of candesartan 
on ERP, but candesartan attenuated significantly the lengthening of conduction time and 
also shortened the duration of induced AF compared to a sham group (Kumagai et al. 
2003). As the ventricular rate was not controlled this result might be explained by 
ventricular myopathy, similar to that observed in models with ventricular tachypacing, 
causing markedly increased tissue concentrations of AngII as well as atrial functional and 
structural remodeling (Li et al. 1999, Cardin et al. 2003, Hanna et al. 2004). 
 
In CHF or hypertension models of AF changes in atria resemble those observed in AF 
patients, with fibrosis, scarring, slowed conduction, increase in electrical heterogeneity 
and tendency to AF (Frustaci et al. 1997, Li et al. 1999, Allessie et al. 2002, Sanders et al. 
2003a, Boldt et al. 2004, Kistler et al. 2006, Kirchhof et al. 2006). LV dysfunction, 
especially congestive heart failure, hypertension and AF by itself via atrial stasis cause 
atrial stretch that is a strong stimulator of RAAS (White et al. 1982, Allessie et al. 2002, 
Ehrlich et al. 2006). In a canine CHF model caused with rapid ventricular pacing Hanna et 
al. demonstrated that structural changes and increase of AngII concentration was 






animals in CHF models are treated with RAAS-suppressing medication before ventricular 
tachypacing, increase in AngII concentration is prevented, apoptosis is suppressed and an 
increase in fibrous tissue content is diminished. However, leukocyte infiltration and cell 
death rate are not affected (Li et al. 2001, Cardin et al. 2003). In CHF models RAAS 
suppression has also attenuated the reduction of atrial contraction and diminished the 
increase of dilatation, and as a consequence, shortened markedly the duration of AF (Li et 
al. 2001, Shi et al. 2002, Kumagai et al. 2003, Li et al. 2007).  
 
In a rapid atrial paced canine model  without AV ablation  the above-mentioned 
signs of CHF-caused alterations were seen, but Sakabe et al. also measured P-wave 
duration, expression of connexin43 and sinus node recovery time (Sakabe et al. 2004, 
Sakabe et al. 2005). Enalapril-treated dogs had significantly lower P-wave duration 
lengthening and less over-expression of connexin43, and the prolongation of sinus node 
recovery time was significantly shorter in comparison with the placebo group (Sakabe et 
al. 2004, Sakabe et al. 2005). By these mechanisms RAAS suppression favors SR by 
improving the pacemaker activity of sinus node as well as by inhibiting electrical disparity 
in atrial tissue. 
2.4.2.2 Human studies 
The above-mentioned experimental data are lacking in man. It is not a surprise that genetic 
differences are also associated with AF, and a different angiotensinogen haplotype profile 
has been found in AF patients and controls (Tsai et al. 2004). Patients with pre-operative 
AF in open-heart surgery have had significantly higher expression of ACE and a certain 
mitogen activated protein kinase (Erk1/Erk2) in right atrial appendage specimens 
compared to surgical patients in SR (Goette et al. 2000a). The behaviour of angiotensin 
receptors (AT1 and AT2) seems unsolved so far, because the results have been 
controversial. AT1 receptors were downregulated and AT2 receptors upregulated in right 
atrial samples of AF patients in one study (Goette et al. 2000b), while in another AT1 
receptors were found to be upregulated in the left atrium and unchanged in the right (Boldt 
et al. 2003). ACE is definitely activated and AngII concentration increased in AF, but the 
status of AT receptors might be dependent on the stages of heart disease and atrial failure. 
Patients treated preoperatively with ACE inhibitors had lower levels of activated 
Erk1/Erk2 and less expression of collagen I in atrial specimens (Goette et al. 2000a, Boldt 
et al. 2006). 
 
Both ACE inhibitors and ARBs have reduced myocardial fibrosis in myocardial 
biopsies of hypertensive patients (Brilla et al. 2000, Díez et al. 2002, Ciulla et al. 2004). 
This antifibrotic effect of RAAS suppression was superior to both hydrochlorothiazide and 
atenolol in a randomized study setting, and those drugs were also associated with 
reduction of left ventricular stiffness and diastolic dysfunction (Brilla et al. 2000, Díez et 






concentrations of collagen synthesis or degradation markers in venous blood samples 
(Ciulla et al. 2004, Nomura et al. 2008). 
 
In a non-randomized study, patients with an ACE inhibitor before an invasive 
electrophysiological examination had a lower incidence of abnormal, fractionated atrial 
electrograms (Shibata et al. 2006). Electrophysiological advantage from RAAS 
suppression has non-invasively been detected as shortened P-wave duration both with 
SAECG and with 12-lead ECG. Shorter P-wave duration was also associated with lower 
recurrence risk of AF (Zaman et al. 2004, Fogari et al. 2008, Nomura et al. 2008). 
 
With antihypertensive therapy, an enlarged left atrium (LA) reduces in size, which has 
also been noted with ACE inhibitors (Gottdiener et al. 1998, Tsang et al. 2006). Besides 
having a systemic antihypertensive effect, RAAS suppression also decreases left atrial 
filling pressure (Mitrovic et al. 2003). These findings  a reduction of atrial size and 
pressure  are crucial at the initiation of AF. Parallel with improvement in atrial electrical 
and structural remodeling, RAAS suppression also improves atrial functional remodeling 
by improving atrial emptying (Tsang et al. 2006). 
2.4.3 Suppression of the RAA system and AF – clinical data 
The first hints of the beneficial effect of suppression of RAAS on AF were achieved in the 
middle of the 1990s from two small, but placebo-controlled prospective studies in patients 
with congestive heart failure (Gürlek et al. 1994, van den Berg et al. 1995). A positive but 
statistically insignificant effect with ACE inhibitor was found as a diminished amount of 
AF after electrical CV. The studies were based on the assumptions that ACE inhibition 
induces a positive potassium balance, improves hemodynamics and attenuates adrenergic 
drive. 
 
In a post-hoc analysis of the TRACE trial of those 1,577 patients who had SR on the 
randomisation ECG, 2.8% allocated to trandolapril and 5.3% allocated to placebo 
developed ECG-documented AF during the 2- to 4-year follow-up (p < 0.01) (Pedersen et 
al. 1999b). In the GISSI-3 trial a 24% reduction in the incidence of in-hospital AF in 
patients randomised to lisinopril + nitrates compared to the placebo group was 
documented, while the effect of lisinopril alone was only 8% and non-significant (Pizzetti 
et al. 2001, Healey et al. 2005).  
 
The first hypertension studies that evaluated the incidence of AF were the CAPPP and 
STOP-H-2 trials (Hansson et al. 1999a, Hansson et al. 1999b). In both trials “new 
antihypertensive drugs” (ACE inhibitors or dihydropyridine Ca-channel blockers) were 
compared to “conventional antihypertensive drugs” (diuretics or -blockers) with no 
significant differences in preventing cardiovascular morbidity and mortality. Either the 
frequency of new AF did not differ between the allocated groups in those trials when AF 






large-scale registry study was performed by L’Allier et al., who investigated the use of 
ACE inhibitors and the risk of AF in hypertensive patients (L’Allier et al. 2004). Patients 
with ACE inhibitors (12 600 patients) had a hazard ratio of (HR) 0.85 for the incidence of 
new-onset AF, and 0.74 for AF-related hospitalisations; both results were statistically 
significant (L’Allier et al. 2004). The most recent analysis of AF in a hypertension trial is 
from the VALUE trial (Schmieder et al. 2008). Based on the centrally analysed ECGs, 
treatment with valsartan reduced new AF (HR 0.83) and new persistent AF (HR 0.68) 
compared to the amlodipine arm. A lower amount of AF was recorded despite greater 
reduction of blood pressure and higher regression in LVH in the amlodipine arm 
(Schmieder et al. 2008). 
 
In randomized prospective controlled trials in patients with heart failure three post-hoc 
analyses of the incidence of AF and the association of RAA system suppressing drugs 
have been completed (Vermes et al. 2003, Maggioni et al. 2005, Ducharme et al. 2006). In 
the SOLVD, CHARM and Val-HeFT trials patients with stable, chronic heart failure were 
randomized to enalapril, candesartan, valsartan or placebo, and cardiovascular mortality 
and morbidity was analyzed. In a post-hoc analysis at a single SOLVD study centre the 
risk of development of ECG-documented AF was reduced with enalapril with a HR of 
0.22 (p < 0.001) (Vermes et al. 2003). In the Val-HeFT trial AF was defined as an adverse 
event, but in the CHARM trial new AF was a prespecified as a secondary outcome. The 
use of valsartan and candesartan were associated with a reduced amount of AF with HRs 
of 0.80 and 0.67, respectively, both those differences being statistically significant 
(Maggioni et al. 2005, Ducharme et al. 2006). 
 
The patient profiles were different in the HOPE, ONTARGET and TRANSCEND 
trials, which had more patients with signs or risk factors of atherosclerosis. In those trials 
an ACE inhibitor, ramipril, or an ARB, telmisartan, did not decrease the incidences of new 
AF between the groups (Yusuf et al. 2000, ONTARGET Investigators 2008, 
TRANSCEND Investigators 2008). 
 
The efficacy of ACE inhibitors or ARBs preventing AF relapse after electrical CV has 
been evaluated in four randomized studies. In their first study, Madrid et al. treated AF 
patients with amiodarone or amiodarone plus irbesartan (150 mg/d or up to 300 mg/d in 
hypertensive patients) for a mean of 28 days before an electrical CV. No difference was 
observed in success rate in either pharmacological restoration of SR before the CV or 
electrical CV, but at the end of the follow-up (median 254 days) 80% patients in the 
irbesartan plus amiodarone group had remained in SR, compared to 56% in the 
amiodarone alone group, p = 0.007 (Madrid et al. 2002). In their second and smaller study 
Madrid et al. compared two different doses of irbesartan (150–300 mg) combined with 
amiodarone or amiodarone alone for restoration and maintenance of SR in lone AF 
patients (Madrid et al. 2004). At the end of the follow-up (median 220 days) 77% of 
patients with amiodarone plus irbesartan 300 mg/d, 65% of patients with amiodarone plus 






The difference between the first and third group was statistically significant (p = 0.01); the 
other comparisons were statistically non-significant (Madrid et al. 2004). 
 
Enalapril was used by Ueng et al. in their study to assess whether cardioversion 
outcome could be improved by an ACE inhibitor (Ueng et al. 2003). The immediate result 
of CV did not differ between the groups. However, both at four weeks after the CV and at 
the end of the follow-up period (median 270 days) patients with enalapril had maintained 
SR significantly more often; 84% vs. 61% and 74% vs. 57%, respectively. An interesting 
finding in this study was that patients receiving enalapril had significantly fewer atrial 
premature beats (APB) both after 2 minutes as well as four weeks after the CV, APBs 
associating strongly with immediate AF relapses (Ueng et al. 2003). Tveit et al. completed 
a randomised, double-blind, placebo-controlled study to examine the ARB candesartan in 
preventing recurrences of AF after electrical CV without any antiarrhythmic medication 
(Tveit et al. 2007). No difference in the quantity of AF was detected between the 
randomisation groups. All in all, electrical CV was successful in 86% of the patients, and 
during the six-month follow-up 68% of those successfully cardioverted had an AF relapse 
(Tveit et al. 2007). 
 
In patients with paroxysmal AF or without a recent CV RAAS stimulation caused by 
long-standing AF is not present. The mechanism of RAAS inhibition in those cases is not 
directed against atrial remodeling caused by AF itself, but RAAS inhibition acts 
nevertheless against the primary mechanisms of AF. Fogari et al. have completed two 
studies in patients with hypertension and paroxysmal AF. In the first one at the end of the 
median follow-up of 299 days 88% of the patients with losartan and amiodarone were 
without AF, compared to 65% in the group with amlodipine and amiodarone (p = 0.008) 
(Fogari et al. 2006). In the second study they randomised patients to three different 
medications: valsartan, ramipril or amlodipine, and no antiarrhythmic medications were 
allowed. The reduction in blood pressure was similar, but valsartan and ramipril were 
more effective than amlodipine in preventing new episodes of AF (recurrence of AF 16%, 
28% and 47%, respectively). In this study the reduction of P-wave dispersion measured 
from specifically instrumented 12-lead ECG seemed to be the greatest in the valsartan 
group (Fogari et al. 2008). 
 
In patients with lone paroxysmal AF amiodarone alone was compared to amiodarone 
plus losartan or amiodarone plus perindopril in a Chinese study (Yin et al. 2006). This 
study was prospective and randomised, but the drugs were given in an open-label fashion. 
A significant reduction of AF recurrence was demonstrated in the groups with RAAS 
inhibition plus amiodarone when compared to the amiodarone only group, while no 
difference was found between the losartan and perindopril groups in the recurrence of AF: 






2.4.4 The RAA system and AF – synopsis 
The active endproduct of RAAS  AngII  causes vasoconstriction, increases fibroblast 
proliferation and cardiac hypertrophy and arouses arrhythmias by activating AT1 
receptors. Renin inhibitors, ACE inhibitors and ARBs suppress the RAA system, and all 
these drug groups have antiarrhythmic effects both in experimental animal models and in 
humans. A reduction in the incidence of AF with RAAS suppression has been studied in 
patients with AMI and LV dysfunction, in AMI patients and in patients with heart failure. 
Variation in hazard ratios (0.22 – 0.92) as well as the numbers of patients and incidence of 
AF is large, and AF suppression has not been statistically significant in all of the studies. 
In post-hoc analyses of hypertension trials and in trials studying patients with 
atherosclerosis but without marked hypertension or heart failure RAAS suppression has 
not been associated with a diminished risk of AF (Hansson et al. 1999a, Hansson et al. 
1999b, Salehian et al. 2007, ONTARGET Investigators 2008, TRANSCEND Investigators 
2008). In the VALUE trial the incidence of new AF was analysed in a prespecified manner 
with ECG data, and ARB treatment had a 0.83 hazard ratio for new AF compared to the 
control group (Schmieder et al. 2008). In addition, a positive effect of RAAS suppression 
has been documented in some small but randomised studies focusing especially on AF 
(Fogari et al. 2006, Yin et al. 2006, Fogari et al. 2008). In prospective randomised 
cardioversion studies there have been differences in patient profiles as well as in the 
duration of AF. The only one that failed to prove any benefit from RAAS suppression was 
performed without amiodarone, and it has been argued that amiodarone might have had a 
“bridging effect” preventing early recurrences of AF and providing time for reverse 
remodeling enhanced with RAAS suppression (Madrid et al. 2002, Ueng et al. 2003, 
Madrid et al. 2004, Tveit et al. 2007). 
 
It seems that in populations with advanced hemodynamic abnormalities and therefore 
also a more activated RAA system, the suppression of this system has the highest benefits 
in preventing AF. The incidence of AF has also been the highest in those patient groups. 
This more pronounced effect of RAAS suppression in patients with more serious heart 
disease is also documented in a single trial (Ducharme et al. 2006). RAAS stimulates atrial 
electrical, structural and functional remodeling begetting AF, the antifibrotic effects of 
RAAS suppression drugs being probably the main mechanism behind the reduction in the 







2.5.1 History of cardioversion 
“It is relatively easy to perform a successful cardioversion, but although the rhythm may 
be altered, the natural history of the disease is not changed”  
Turner and Towers 1965 
 
Antiarrhythmic properties of cinchona bark were already recognised in the 18th century, 
and during the 1920’s the use of quinidine for termination of AF was established (Viko et 
al. 1923, Parkinson and Campbell 1929, Lüderitz 2002b). Many of the patients who 
achieved SR felt better and some of them could return to their normal activities, while 
patients who retained AF had a much poorer clinical course. The importance of a short 
history of AF in achieving a favorable result in restoration and maintenance of SR with 
quinidine was also noticed very early (Viko et al. 1923, Parkinson and Campbell 1929). 
 
During the 1930s the induction and termination of ventricular as well as atrial 
fibrillation with electrical shock in animals was established (Wiggers and Wégria 1940). 
The termination or defibrillation of ventricular fibrillation in man was documented by Zoll 
et al., who studied intensively the external electrical stimulation of the heart with 
alternating current (AC) (Zoll et al. 1956, Gibson et al. 1956). However, it was already 
found in the 1930s that alternating electrical current was more dangerous in stimulating 
ventricular arrhythmias than direct current (DC) (Wiggers and Wégria 1940). Clinical 
application of electrical countershock became possible with the thorough work of Bernard 
Lown, who also launched the term “cardioversion” (Lown et al. 1962, Lüderitz 2002b). 
His group established that DC was more effective and safer in terminating arrhythmias 
than AC, and that ventricular arrhythmias could be avoided with stimulus synchronised 
within the terminal part of the QRS complex (Lown et al. 1962). Since then, 
implementation of defibrillators using impedance compensated biphasic waveforms in the 
1990s is the most noticeable evolution in the field of external cardioversion (Cooper et al. 
1997, Mittal et al. 2000, Adgey and Walsh 2004, Gall and Murgatroyd 2007). 
2.5.2 Results of cardioversion of atrial fibrillation 
2.5.2.1 Immediate results of cardioversion  
In his historical paper Lown et al. reported results of “synchronised cardiac 






In eleven cases out of thirteen (85%) SR was restored with monophasic waveform given 
by the developed capacitor  “results seeming encouraging” (Lown et al. 1962). In 1967 
the same group published their results of 456 episodes of atrial defibrillation in 350 
patients, documenting restoration of SR in 94% of the occasions (Lown 1967). 70% of 
patients had rheumatic valve disease and energy requirement, and the success rate was 
directly related to the duration of AF before the CV (Lown 1967). 
 
The other pioneers of electrical cardioversion during the 1960s got very similar results, 
reaching 77-90% success rates in the immediate result of CV with monophasic stimulus 
(Oram and Davies 1964, Turner and Towers 1965, Bjerkelund and Orning 1968, Radford 
and Evans 1968, Szekely et al. 1970). Shorter duration of AF, thyrotoxicosis, absence of 
P-terminal force and coarse fibrillating waves in ECG, and absence of or corrected mitral 
valve disease were factors documented in association with higher proportion of restoration 
of SR. This better instantaneous result was also observed in patients with lone AF (Oram 
and Davies 1964, Turner and Towers 1965, Lown 1967, Bjerkelund and Orning 1968, 
Radford and Evans 1968, Scott et al. 1968, Szekely et al. 1970). With defibrillators 
providing biphasic waveform introduced in the 1990s electrical CV has achieved success 
rates of 90 - 95% (Adgey and Walsh 2004, Cooper et al. 1997, Mittal et al. 2000, Gall and 
Murgatroyd 2007). To minimise the number of shocks given as well as the amount of total 
energy it is recommended that at least 200 J is applied when using monophasic waveform 
and at least 150 J when using biphasic waveform. Anterior-posterior electrode 
configuration has given some benefit over anterior-apical positioning in some studies, and 
it might increase the probability of successful CV (Adgey and Walsh 2004, Kirchhof et al. 
2005, Fuster et al. 2006, Gall and Murgatroyd 2007). 
 
Even though only approximately 4% of the current given traverses the heart during 
external defibrillation in humans, a good immediate success rate of electrical CV is 
achieved with monophasic shocks as well (Lerman and Deale 1990, Adgey and Walsh 
2004, Gall and Murgatroyd 2007). In the 1960s it was very soon noted that “though atrial 
fibrillation can now be readily terminated, maintenance of SR continues as the central 
problem”, and the focus has turned away from assessing features that only predict the 
initial CV result (Lown 1967).  
2.5.2.2 Long-term results of cardioversion 
In the 1960s most of the patients referred for electrical CV had (rheumatic) valve disease 
and the duration of AF was very long, even up to many years. In such circumstances the 
atria have been exposed to a long-lasting stretch causing atrial remodeling, and the overall 
result  patients restored and SR maintained for one year  was less than 30% (Oram and 
Davies 1964, Bjerkelund and Orning 1968, Radford and Evans 1968, Scott et al. 1968, 
Szekely et al. 1970). Duration of AF has been the major characteristic predicting the 
maintenance of SR, and it has repeatedly been reported to have this central role in recent 






many years decreased the likelihood of SR, but thereafter the cut-off point of the duration 
of AF for a better CV result has been shortened to less than two months (Lown 1967, 
Bjerkelund and Orning 1968, Szekely et al. 1970, Dittrich et al. 1989, Alt et al. 1997, 
Verhorst et al. 1997, Antonielli et al. 2002, Biffi et al. 2002, Guo et al. 2003). With 
transesophageal echocardiography-guided cardioversion the delay before CV can be 
noticeably shortened, but improved long-term results have not so far been established 
(Roijer et al. 2000, Weigner et al. 2001, Klein et al. 2001). 
 
In practice, all the documented risk factors for poorer restoration and maintenance of 
SR with CV illustrate atrial remodeling or are surrogates of remodeling. As basic clinical 
characteristics, advanced age, heart failure and valvular disease have been associated with 
poorer outcome and vice versa, lone AF has been associated with better outcome of CV 
(Oram and Davies 1964, Bjerkelund and Orning 1968, Radford and Evans 1968, Van 
Gelder et al. 1996, Alt et al. 1997, Berry et al. 2001, Raitt et al. 2006). Patients with 
coronary artery disease and thyrotoxicosis have had a somewhat better rate of restoration 
and maintenance of SR (Radford and Evans 1968, Scott et al. 1968, Szekely et al. 1970, 
Alt et al. 1997, Raitt et al. 2006). The reasons for this might be that coronary artery 
disease patients have more often had beta blocking agents, and thyrotoxicosis patients 
having more often a healthy, intact heart.  
 
Atrial electrical remodeling as shortened APD and ERP reduces the outcome of CV 
(Olsson et al. 1971, Biffi et al. 2002, Okumura et al. 2005). In the frequency analysis the 
frequency of atrial electrical activity during AF depends on the electrical properties of the 
atria and is highly correlated with atrial ERP (Capucci et al. 1995). The frequency of 
fibrillatory signals can be measured as AF current length (AFCL) or as frequency, and 
both these methods have confirmed their prognostic accuracy to predict maintenance of 
SR (Langberg et al. 1998, Fynn et al. 2001, Holmqvist et al. 2006a). Besides the frequency 
of fibrillation signal, also the organisation of those frequencies as less organised rhythms 
or less harmonisation is associated with higher propensity to AF relapse (Holmqvist et al. 
2006b). More organised atrial electrical activity prior to CV was already documented by 
Oram and Davies, who found that higher amplitude of F-waves favored the maintenance 
of SR (Oram and Davies 1964). Macroscopic atrial electrical remodeling is observed as 
lengthened and more dispersed P-wave, and both 12-lead ECG as well as SAECG 
techniques have demonstrated their capacity to find patients with an increased risk of AF 
relapse (Opolski et al. 1997, Aytemir et al. 1999, Raitt et al. 2000, Guo et al. 2003, 
Perzanowski et al. 2005, Raitt et al. 2006). Along with lengthened P-wave duration, 
diminished amplitude of the end of the P-wave is associated with poorer CV result 
(Opolski et al. 1997, Aytemir et al. 1999, Guo et al. 2003). An interesting finding in some 
studies has been that while duration of AF and electrophysiological measurements have 
predicted the result of CV in univariate analyses, only electrophysiological results as 
markers of atrial remodeling have remained statistically significant in multivariate 
analyses (Dixen et al. 2004, Dogan et al. 2004, Okumura et al. 2005). This indicates that 
electrical remodeling is the factor behind poorer probability of SR, and AF duration is a 







The size of the atria has an essential role in propagation of AF, enlarged atria allowing 
more electrical wavelets to wander over atrial tissue.  Lown already noted that patients 
with a markedly enlarged left atrium had a high risk of AF relapse, and when the size of 
atria became measurable with echocardiography, the size of the (left) atrium could be used 
as a predictor of the maintenance of SR (Lown 1967, Ewy et al. 1980, Höglund and 
Rosenhamer 1985). Thereafter, atrial size has been one of the most often reported factors 
associating with restoration and maintenance of SR (Dittrich et al. 1989, Alt et al. 1997, 
Verhorst et al. 1997, Antonielli et al. 2002, Dogan et al. 2004, Fuster et al. 2006).  
 
More advanced functional remodeling measured as markedly decreased flow velocities 
in atrial appendages as well as decreased atrial emptying (mitral A-wave) have been 
documented in patients prone to AF relapse (Verhorst et al. 1997, Antonielli et al. 2002, 
Kinay et al. 2002, Dogan et al. 2004). Kinay et al. also measured the time interval from 
initiation of P-wave to the starting point of left atrial appendage ejection wave, illustrating 
nicely the association between atrial electrical and functional action. They found that the 
lengthening of this interval was an independent predictor of AF relapse – most probably as 
a sign of altered interatrial conduction because of conducting tissue fibrosis. The mean 
atrial size was not different in the patients with or without an AF relapse in this study 
(Kinay et al. 2002). 
 
After cardioversion reverse remodeling takes place, and the probability of sustained 
SR increases over time. It makes sense to suppose that better reverse remodeling improves 
the maintenance of SR. The energy of atrial P-wave signal measured by SAECG seems to 
decrease more in those patients who remain in SR compared to patients with an AF 
relapse (Stafford et al. 1998, Guo et al. et al. 2003). However, the clinical applications of 
these methods are lacking. 
2.5.3 How to improve the result of cardioversion in clinical practice 
The duration of AF before CV has a central role in terms of the result of CV, and it is also 
the least demanding way to improve the CV result. In clinical practice, problems with 
anticoagulation therapy  subtherapeutic INR values  are the main factor in lengthening 
the delay before elective CV, and effort should be put into improving anticoagulation 
therapy as well as logistics between general practitioners and CV centers (Kim et al. 
2001). Another approach aimed at shortening the duration of AF before CV is to employ 
transesophageal echocardiography-guided cardioversion (Roijer et al. 2000, Weigner et al. 
2001, Klein et al. 2001). 
 
Modern biphasic external defibrillators stop AF in about 95% of the cases; this can 
only be exceeded with the use of internal CV (Gall and Murgatroyd 2007). The probability 
of immediate recurrence of AF can be decreased with pre-treatment with class Ia and Ic 






amiodarone having the best efficacy (Van Noord et al. 2002, Fuster et al. 2006). RAAS-
suppressing medications decrease the amount of atrial premature beats and improve sinus 
node function, both of which might also improve the immediate result of CV (Gürlek et al. 
1994, Sakabe et al. 2005).  
 
Overload of Ca2+-ions in atrial cells during AF can be reduced with the use of 
intracellular calcium-lowering medications (-blocking agents, diltiazem and verapamil), 
which also reduce the number of early AF recurrences (Tieleman et al. 1998, De Simone 
et al. 1999, Villani et al. 2000). However, non-dihydropyridine Ca-channel blockers seem 
to have only modest, if any, effect on preventing late AF recurrences (Villani et al. 2000, 
Hemels et al. 2006). In adjunction with Class I or III antiarrhythmic medication, verapamil 
has increased the maintenance of SR (De Simone et al. 2003). 
 
All class Ia, Ic and class III antiarrhythmic drugs improve the maintenance of SR. 
However, these drugs have adverse effects and in older studies class Ia drugs were also 
associated with increased mortality. Of the class II drugs  -blocking agents  metoprolol 
and bisoprolol have proven efficacy in preventing AF relapse after CV (Kühlkamp et al. 
2000, Plewan et al. 2001). Of the drugs currently on the market, amiodarone has the best 
efficacy with a low pro-arrhythmia risk, but it has a very challenging adverse event profile 
in long-term use (Fuster et al. 2006, Lafuente-Lafuente et al. 2007). RAAS-suppressing 
medication and also statin therapy as non-antiarrhythmic treatments seem to improve 
modestly the restoration and maintenance of SR after electrical CV, their benefit coming 
mainly from acting against atrial fibrosis and inflammation (Madrid et al. 2002, Ueng et 
al. 2003, Madrid et al. 2004, Fuster et al. 2006, Ozaydin et al. 2006) 
 
When the rhythm strategy  restoration and maintenance of SR  is set as a goal in an 
AF patient, repeated cardioversions and application of antiarrhythmic medications are 
usually needed. Repeated CVs combined with antiarrhythmic drug treatment increased 
markedly the proportion of patients in SR (Roussane et al. 1984, Crijns et al. 1991, 
Bertaglia et al. 2002).  This kind of policy seems to be especially successful as an 
aggressive strategy aiming at immediate CV after an AF relapse (Bertaglia et al. 2002, 
Nergårdh et al. 2007). These results also warrant the finding that reverse remodeling 
occurring after CV and demonstrable during SR vanishes over time after an AF relapse 







2.6.1 Theory of magnetocardiography 
Activation and contraction of the heart is generated by changing concentrations of extra- 
and intracellular ions. Moving ions create changing electrical currents that are 
extracorporeally measurable by electrocardiography  ECG. Like every electrical current, 
also the current created by the heart generates a magnetic field (the Biot-Savart law), and 
as the nature of this source changes, this magnetic field also changes and is 
extracorporeally measurable by magnetocardiography  MCG (Malmivuo and Plonsey 
1995). 
 
An ECG lead always measures the sum of electrical activities, and a lead can even be 
silent if the activities have opposite directions (Baule and McFee 1963). However, the 
electric currents set up a detectable magnetic field. Modern multichannel MCG devices 
have good spatial resolution accuracy, and measured in close proximity, cardiac 
electromagnetic sources unattainable with ECG can be detected (Fenici et al. 1992, Koch 
2004). The flux of currents in the human torso is also affected by the differences in 
conductivity and boundaries of the torso, while MCG is less dependent of these sources 
(Hosaka et al. 1976, Siltanen 1989, Fenici et al. 1992). MCG is furthermore less sensitive 
to electrical resistance due to pulmonary emphysema and pericardial effusion, and as a 
contactless modality, the MCG signal is not troubled by the noise of electrode-skin 
connection, as is the case with conventional ECG technique (Siltanen 1989, Fenici et al. 
1992, Koch 2004).  
 
In theory, maybe the greatest advantage of MCG over ECG is that it is more sensitive 
to the electrical sources that are tangential to the chest (Nousiainen et al. 1986, Siltanen 
1989, Fenici et al. 1992). In a healthy, intact heart, most of the ventricular activation 
proceeds transmurally from the endocardium to the epicardium, directed radially towards 
the ECG leads. Atrial activation is mostly tangential to the heart and chest wall, as is the 
activation of the His-Purkinje system as well as ventricular activation interfered by 
myocardial scars, the sources  in theory  more achievable with MCG (Siltanen 1989, 
Fenici et al. 1992). The source of both ECG and MCG is the electrical activity of the 
heart; therefore, P-, QRS-, T- and U-waves are also recognised in the MCG, and the same 
nomenclature of those deflections is applied (Figure 5).  
 
Figure 5. Relationships between detected signals of single ECG and MCG channels, and 
schematic illustration of instrumentation of ECG and MCG (axial gradiometer with 
two magnetometer coils). SQUID: Superconducting Quantum Interference Device 
Used with permission from Yamada S. (Yamada and Yamaguchi 2005). 
 
2.6.2 Instrumentation of magnetocardiography 
The human cardiac magnetic field was first detected by Baule et al. with two specially 
designed magnetometer coils (Baule and McFee 1963). The recorded signal was extremely 
small and noisy, and was measurable only “several dozen yards from the nearest source of 
interference”, but had the recognisable feature of a cardiac signal (Baule and McFee 
1963). Magnetic field of the heart is approximately 0.1 - 100x10-12 Tesla (pT), that is 10-6 
of the earth’s magnetic field and 10-3 of the background magnetic field of urban 
environment, and special instrumentation is needed to achieve an acceptable signal-to-
noise ratio. 
 
A major improvement in MCG was achieved in the late 1960s when David Cohen 






Device (SQUID) (Cohen et al. 1970). The SQUID technique applies a supraconducting 
state at a very low temperature reached with a vacuum flask (“dewar”) with liquid helium 
at 4.2 K (-269C) where the MCG coil(s) and SQUID amplifier(s) are immersed, which 
allows very low intrinsic instrumental noise (Cohen et al. 1970). With a supraconducting 
state, large coils with up to millions of turns were not needed and MCG was even 
measurable with just one copper coil. When a magnetometer coil measures cardiac 
magnetic field it always detects the background environmental magnetic field as well. To 
improve the signal-to-noise ratio magnetometers have reference coil(s), and when the 
common signal of the magnetometer coil and this compensation coil is subtracted, the 
external noise is reduced. Gradiometers have two or more axial or planar magnetometer 
coils that further reduce residual noise (Figure 5). With modern, sophisticated signal 
averaging techniques and software-based interference suppression methods the signal-to-
noise ratio can be additionally improved (Koch 2004). During the 1960s and 1970s  
multisite MCG mapping was completed when the signal was recorded by moving the 
dewar point by point over the thorax in a placement grid. Currently multichannel devices 
are most often utilized and multichannel MCG mapping can be achieved with a single 
registration (Koch 2004). 
 
There are two main routines to express MCG data: expressing the signal as scalar time-
series like traditional ECG having P-, QRS-, T- and U-waves (Figure 5), or constructing a 
MCG map (Figure 6). Traditional MCG mapping shows the magnetic isofield strengths 
drawn over the mapped area at a selected time point where the direction and strength of 
the integral of those magnetic forces can be calculated and depicted. Pseudocurrent maps 
can be constructed from magnetic fields giving an intuitive representation of the electrical 
source (Figure 6). 
 
Figure 6. An example of magnetic fields during atrial depolarization from a healthy control 
represented as isofield maps (upper row) and as pseudocurrent maps (lower row). ) 
At left averaged P-wave of all included MCG-channels. The images at right illustrate 
integrals over the whole atrial depolarisation signal and during the first and last 50 
ms of atrial depolarisation signal              











2.6.3 Magnetocardiography and the atria 
2.6.3.1 Findings of atrial signal with magnetocardiography 
Atrial depolarisation spreads over the atria mostly along the atrial wall and tangentially to 
the chest, and this atrial P-wave in MCG has been attainable since the SQUID technique 
was introduced (Cohen and McCaughan 1972, Siltanen 1989). In healthy subjects the P/R 
amplitude ratio in MCG has proven to be at least as high as in ECG, and a biphasic pattern 
of P-wave has been more often evident in MCG (Cohen and McCaughan 1972, Saarinen 
et al. 1974).  
 
Furthermore, in atrial pathology MCG seems to have even better accuracy for 
diagnosis than ECG. In atrial overload the P/R ratio was more marked and sensitivity and 
specificity better for a diagnosis in MCG than in ECG (Saarinen et al. 1974, Sumi et al. 
1986, Takeuchi et al. 1988). Siltanen et al. also noticed that a shift of the PR segment from 
the baseline was very pronounced in MCG both in atrial overload and in hypertrophic 
cardiomyopathy patients, and that phenomenon was suggested to represent atrial 
repolarisation not visible in the corresponding ECG tracings (Siltanen 1989). Even though 
the atrial MCG signal was already recorded more than 30 years ago, reproducibility of the 
atrial MCG signal has not been established. 
2.6.3.2 Magnetocardiography and AF 
The data regarding AF and MCG are few. However, Siltanen et al. were able to document 
coarse fibrillatory waves in AF patients when a noiseless baseline was achieved (Siltanen 
1989). Nakai et al. had a 64-channel MCG device enabling visualisation of the cardiac 
activity integrated with cardiac anatomical silhouette during AF. They demonstrated a 
random micro-re-entry signal around the atrium in AF patients, while the activity in 
patients with atrial flutter had a macro-re-entry character (Nakai et al. 2005). After 
restoration of SR MCG demonstrated an organised activity pattern. They also have shown 
in a frequency analysis that patients who failed to maintain SR after surgical ablation had 
higher atrial fibrillatory frequency in MCG than patients who reached SR (Nakai et al. 
2008). This confirms the findings documented with ECG that AF cycle length is shorter in 
patients prone to AF (Langberg et al. 1998, Fynn et al. 2001, Holmqvist et al. 2006a). 
Preoperative MCG mapping in a patient with mitral valve stenosis and AF made it 
possible to simplify the surgical AF procedure to achieve sustained SR (Kim et al. 2007). 
 
Mäkijärvi et al. focused on patients with pre-excitation syndrome (WPW), some of 
whom had a history of AF attacks. AF patients had more dispersed atrial depolarisation 
distributions compared to WPW patients without AF. Out of the patients with AF 






while 4/6 (67%) of the patients without AF had bipolar MCG maps (Mäkijärvi et al. 
1993). 
 
The atrial magnetic field had changed from organised during SR to completely 
disorganised during AF; moreover, when the rhythm turned to atrial flutter, the magnetic 
field had a circular pattern. In order to confirm their MCG data, this group had 
electrophysiological data of this same experience (Yamada et al. 2003). A clear difference 
was seen between patients with focal automatic tachycardia and AF patients, the former 
showing a significantly less disorganised pattern in time-frequency analysis of MCG. 
Therefore, this kind of analysis might be useful in differentiating between AF with 
multiple wavelets and focal AF with triggered activity, and it might also be valuable for 
evaluating degrees of electrical remodeling in AF patients (Yamada and Yamaguchi 
2005).  
 
Winklmaier et al. performed a MCG study in AF patients during SR after spontaneous 
conversion or electrical CV (Winklmaier et al. 1998). They recorded a multichannel MCG 
and 12-lead ECG, created sum channels from all the MCG channels, and separately from 
anterior and posterior channels as well as from ECG channels. The major focus of this 
study was the duration of the P-wave that was manually measured in each sum channel. 
AF patients had a significantly longer duration of P-wave in all the MCG sum channels 
compared to the controls, whereas the difference was non-significant in the ECG sum 
channel. The mean duration of P-wave in anterior MCG sum channels was 133 ms in AF 
patients compared to 100 ms in the controls. Fragmentation index measuring differences 
between amplitude peaks over the P-wave was also significantly higher in the AF patients. 
This group also constructed MCG field maps from which a particular index (“p score”) to 
estimate homogeneity of the atrial signal was calculated, AF patients having significantly 
lower homogeneity. This study can be criticised in that the control group consisted of 
healthy young men not comparable with the AF patient group (Winklmaier et al. 1998). 
There are no publications comparing patients with persistent AF with a comparable 






3 Aims of the study 
This study was accomplished to evaluate atrial remodeling behind AF and its 
epidemiology, in addition the results of treatment of AF.  The prevention of AF, as well as 
reverse atrial remodeling were elucidated. 
 
The specific aims of the study were: 
 
1. To study the restoration and maintenance of sinus rhythm after their first 
electrical cardioversion in patients with persistent AF. The relations of the clinical 
outcome to patient characteristics, duration of AF, and medication with anti-arrhythmic 
properties, as well as progression to permanent AF were evaluated. 
 
2. To study cardiovascular morbidity and mortality in hypertensive patients 
with ECG-documented LVH and a new-onset AF, as well as to determine whether 
selective angiotensin II type 1 receptor blockade with losartan is more effective than -
blockade with atenolol in reducing the incidence of new-onset AF. 
 
3. To establish the frequency of AF in an AMI population with left ventricular 
dysfunction, and to study the association of AF with the outcome of the patients. 
 
4. To validate recording and processing of atrial depolarisation signals by 
multichannel MCG, and to assess reproducibility of measurement of atrial signal 
variables. 
 
5. To asses if MCG-based atrial signal analysis technique is able to detect atrial 









4 Subjects and methods 
4.1 Study I 
The subjects were one hundred and eighty-three AF patients of the population of 440,000 
served by the Helsinki City Hospital who underwent their first elective cardioversion in 
Helsinki City Hospital during 1997. None of the 183 patients had AF associated with 
recovery phase of open cardiac surgery, which was the only exclusion criterion in this 
population-based evaluation. 
 
The patients were found from the patient registers kept at the Helsinki City Hospital 
sites that performed elective electrical CVs in 1997. Clinical data, including diagnoses 
made by the physicians in charge, were obtained retrospectively from the hospital records. 
Follow-up data for a one-year period after the CV was aimed at, and if needed, these data 
were completed through direct contacts with the patients’ doctors. The purpose of the 
study was to evaluate the result of the CV in terms of SR. The delay between ECG-
verified diagnosis of AF and cardioversion was chosen to represent the duration of 
arrhythmia because of the difficulty of establishing the actual duration of AF. Relapse into 
AF was ECG verified, but timed according to patient’s subjective symptoms, if present. 
Patients in whom cardioversion was not successful were considered early relapses of AF 
in order to include these patients in the analysis.  
4.2 Study II 
The LIFE trial was a prospective, randomised, double-blinded study that compared the 
long-term effects of antihypertensive therapies based on an ARB, losartan, with those 
based on a -blocker, atenolol, in 9,193 patients with hypertension and LV hypertrophy. 
The present study evaluated the 8,851 patients with ECG-documented SR at baseline and 
no history of AF who were thus at risk of developing new AF. 
 
New-onset AF was identified from annual in-study ECGs that underwent Minnesota 
coding for AF at a single ECG core center. The care of the patients with new-onset AF 
was left to the discretion of local investigators and the patients’ own doctors. This study 
analysed the number of patients faced by the primary composite endpoint, which was the 
first occurrence of cardiovascular death, fatal or nonfatal stroke, and fatal or nonfatal 
myocardial infarction. Additional endpoints included all-cause mortality and the first 
occurrence of each component of the composite endpoint. All the reported endpoints were 
verified by independent monitors, and adjudicated by an independent committee.  
 
4.3 Study III 
The OPTIMAAL trial compared losartan with an angiotensin-converting enzyme 
inhibitor, captopril, on mortality and morbidity in patients with evidence of heart failure or 
left ventricular dysfunction and/or anterior Q-waves after AMI. The trial included 5,477 
patients. In the present study were included those 655 patients who had AF at baseline 
plus those 345 patients who developed new AF during the follow-up period. The total 
number of patients with AF in this OPTIMAAL trial subanalysis was therefore 1,000.  
  
AF was recorded on the case report form (CRF) as a pre-existing medical condition at 
the time of randomisation, or as an adverse experience based on ECGs taken at baseline or 
at follow-up visits during the study. AF at baseline was defined as either AF recorded on 
the medical history CRF or seen on ECG at randomisation. New-onset AF was defined as 
AF detected on an ECG after the randomisation in a patient without baseline AF. 
4.4 Studies IV and V 
In Study IV, the methodological basis of our MCG process was set up, and we examined 
recording and processing of atrial depolarization signals by multichannel MCG and 
assessed the reproducibility of the method. The study population consisted of ten healthy 
volunteers with no history of arrhythmia and nine patients with paroxysmal lone AF. To 
assess the reproducibility, recordings were repeated at least 1 week apart (from 1 week to 
6 months). 
 
Study V was completed to evaluate differences between AF patients weighed against a 
comparable control group. Twenty-six patients with persistent AF who underwent elective 
electrical CV after appropriate anticoagulation with no hemodynamically significant 
valvular disease, history of MI, other structural heart disease or use of class I or III 
antiarrhythmic medications were included. 24 age- and disease-matched men and women 
without history of AF served as controls. MCG, signal-averaged ECG (SAECG) and 
Doppler echocardiography were performed 1 to 3 hours after CV, and in those who stayed 
in SR, 1 month later as well. Control subjects had the tests performed once. 
 
The same MCG method was used in both Studies IV and V and was as follows: The 
MCG recordings were performed in a magnetically shielded room (ETS-Lindgren 
Euroshield Oy, Eura, Finland) in the BioMag Laboratory of Helsinki University Central 
Hospital (Figure 7). A multi-channel cardiomagnetometer (Neuromag Ltd, Helsinki, 
Finland) was used. It was equipped with 33 triple-sensor direct current SQUID units, in 
each of which a magnetometer was overlaying 2 perpendicular planar gradiometers. 
Sensor units were arranged on a cylindrical, slightly curved surface with a diameter of 30 
cm. The magnetic field component perpendicular to the sensor array surface (Bz) was 
measured. In these studies, signals recorded with magnetometers were used because of 






were in supine position and the cardiomagnetometer sensor array was placed over anterior 
chest, the center positioned at 15 cm below the jugular notch and 5 cm to the left of the 
midsternal line (Figure 7) Simultaneously with MCG, a 3-lead orthogonal SAECG with 
bipolar lead placement was registered using disposable Ag/AgCl electrodes. Signals were 
recorded in SR over 5 minutes. 
 
 
Figure 7. MCG measurement with the cardiomagnetometer and positioning of the sensor array 
with 30 cm diameter containing 33 sensor units in regard to the subject’s torso. The 
center of the array is located 15 cm below the jugulum and 5 cm to the left of the 
center of the chest. 
 
Analogue band-pass filtering of 0.03 to 300 Hz was applied and an analogy-to-digital 
conversion was made at sampling frequency of 1 kHz. P-wave averaging was based on 
QRS-triggering with the predominant P-wave morphology chosen for a template. P-wave 
complexes were accepted if they matched the template with cross-correlation of at least 
95% for ECG-leads and 90% for MCG-channels. The goal was to have at least 100 atrial 
complexes averaged. In Study IV the averaged signals were highpass-filtered using 
bidirectional Butterworth-type, fourth-order filter having corner frequency at 25, 40, and 
60 Hz to test different filterings, while in Study V only 40 Hz filter was applied. Noise 
was determined as the mean signal amplitude over a 40-millisecond time window in the 
TP segment. MCG-channels with a mean noise level greater than 20 fT were rejected. The 
onset and offset of atrial complex were automatically determined. The onset was defined 
as the midpoint of a 5-millisecond interval where the average amplitude first exceeds the 
mean noise level by 10 fT when approaching the atrial complex. The offset of the atrial 






window between the atrial and QRS complexes was determined and set as reference noise 
level. Then, beginning from inside the atrial complex, the offset was defined as the 
midpoint of a 5-millisecond interval where the mean atrial signal amplitude declines to 
less than 10 fT above the reference noise level. The definitions for atrial signal onset and 
offset for SAECG were determined using a 1.0 V limit in analogy to 10 fT in MCG. 
More detailed signal analyses and variables used in Studies IV and V are described in the 
original publications. 
4.5 Statistical methods 
Study I 
In all the studies, data were expressed as mean  SD, or as median when a variable with 
skewed distribution was considered, or number and percentage (%) of patients. The 
outcome in Study I was defined as the combined result of both restoration and 
maintenance of SR, and Kaplan-Meier survival plots were prepared, SR being considered 
survival. Covariates with a p-value of less than 0.20 in the log rank test were entered in the 
Cox proportional hazards regression analysis for multivariate modeling. To compare 
characteristics between the subgroups 2-test, Fisher exact test or two-sample t-test (two-
tailed), when appropriate, was performed. A p-value of less than 0.05 was considered 
statistically significant.  
 
Study II  
Potential risk factors were assessed for association with new-onset AF. Cox proportional 
hazards models were used to compare hazard ratios (HRs) between study treatment 
allocation groups (losartan or atenolol) and to evaluate contributions of differences in the 
degree of LV hypertrophy, the Framingham risk score and other covariates. The risk of an 
endpoint associated with new-onset AF as well as the predictors of new AF were assessed 
with univariate proportional hazards regression model, and variables with significant 
effects were moved to multivariate analyses applying the Cox regression model. Two-
tailed p < 0.05 was considered significant. 
 
Study III 
Differences between the groups at baseline were analysed with Student’s t-test for 
continuous variables and Pearson’s 2-test for categorical variables. The risk of 
developing AF associated with various baseline variables was evaluated using age-
adjusted Cox regression models. The risk of total mortality, cardiovascular death, stroke, 
and all-cause hospitalisation associated with AF was analysed in two models. Firstly, 
patients with or without AF at baseline were compared in unadjusted and adjusted Cox 
regression models. Secondly, in patients without AF at baseline, new AF was included as 
a time-dependent co-variate in order to estimate the impact of new-onset AF after AMI. 
The impact of new-onset AF on endpoint risk was illustrated using modified Kaplan-
Meier curves where the cohorts are continually updated with the existence or the 






correspond to the Cox regression model with AF as a time-dependent co-variate. All 
reported p-values are two-tailed, and while no specific level of statistical significance was 
defined, a p-value of 0.001 should be considered to indicate strong evidence in support of 
a true effect. 
 
Study IV 
Correlation between variables was studied by Pearson correlation test. Coefficient of 
variation in repeated measurements was determined by analysis of variance, calculated as 
square root of mean square of within-subject variability divided by the mean of each 
variable (Chinn 1990, Bland and Altman 1996). Coefficient of variation was transformed 
to percentage value by multiplying by 100. Comparison of reproducibility between 
different filtering frequencies and between groups was performed using proportional 
difference, which was calculated as |m1 - m2| / [(m1 + m2)/2] for each subject. 
Differences in measured values and in reproducibility between the groups were examined 
with Student’s t test. A 2-tailed p-value of < 0.05 was considered statistically significant.  
 
Study V 
The differences between patients and controls were calculated using two-sample Student’s 
t-test (two-tailed) or 2-test, when appropriate. Analysis of covariance (ANCOVA) was 
performed when controls and patients were compared both at baseline and at repeated 
measurements including potentially confounding variables. Paired Student’s t-test (two-









5.1 Frequency of atrial fibrillation 
Frequency of AF in Study I can be estimated in perspective of the catchment areas of this 
part of Helsinki City covering 440,000 inhabitants. All the elective CVs of the AF patients 
that are the focus of the present study were performed and registered in the City Hospital 
during the time of the study. Based on the methods used, it was not possible to evaluate 
the prevalence of AF in Helsinki; neither could we estimate predictors of the incidence of 
AF. In Study I 183 patients were studied, and the incidence of patients with persistent AF 
referred for their first elective CV was thus 0.4 /1,000 person years. Our finding that 40% 
of patients with their first cardioversion will progress to permanent AF within one year 
has not been documented before (Figure 8). An interesting finding was that older age was 
associated with acceptance of permanent AF, and also that a longer duration of AF before 
the CV tended to associate with it. 
 
Figure 8. The continuous line depicts restoration and maintenance of sinus rhythm after first 
cardioversion. The dotted line depicts cumulative proportion of patients with the 
decision to accept permanent atrial fibrillation (Perm. AF). 
 
 59
The LIFE trial that was the source for Study II had 9,193 patients with hypertension 
and ECG verified LVH. At baseline, 3.7% of this population with the mean age of 66.9 
years had AF. The characteristics of this cohort with baseline AF is documented in an 
other paper not included in this Thesis, AF patients being for example significantly older, 
less often women, having higher diastolic blood pressure and expression of LVH in ECG 
and especially having more often other cardiovascular co-morbidities (Wachtell et al. 
2005). During the mean follow up of 4.8 years the incidence of new AF was 8.1 per 1,000 
person years. Of the baseline characteristics higher age (HR for every year of age 1.09 p < 





Hg 1.09, p = 0.023) and Cornell voltage duration (HR for 100 mV·ms 1.01, p = 0.030) 
were significantly associated with the incidence of new AF in the multivariate model. 
 
The prevalence of AF at baseline in the OPTIMAAL trial was 12% (655 patients) of 
the total number of 5,477 patients randomised in this trial. As in Study II, patients with AF 
in Study III were significantly older and had significantly more often hypertension, 
ischemic heart disease, congestive heart failure, and cerebrovascular disease compared to 
those who did not have AF at baseline. Patients with AF had also significantly higher 
blood pressure and heart rate at baseline and exhibited more severe Killip class. Of the 
4,822 patients without AF at baseline, 96 (2.0%) developed new-onset AF during the first 
3 months after randomisation, and a total of 345 patients (7.2%) developed new AF during 
the follow-up period. Age-adjusted risks of development of new-onset AF in Study III 
were older age (HR per 10 years 1.66, p < 0.001), male sex (HR 1.65, p < 0.001), history 
of angina (HR 1.56, p < 0.001), more severe Killip class (relative to Class 1, p = 0.002), 
higher heart rate (HR 0.92 per 10 min, p = 0.041) and higher diastolic blood pressure at 
randomisation (HR 1.10 per 10 mmHg, p = 0.043). The results of frequencies of AF in the 
studies of this Thesis are collected in Table 1. 
 
Table 1. Frequency of AF in the studies of this Thesis.  
 CV = cardioversion, HA = hypertension, LV(H) = left ventricular (hypertrophy), 













General population of the catchment 
area of Helsinki; 
n = 440,000 
na. 
0.4 /1,000 referred for CV in 





Age 66.9 y, HA + LVH 
n = 9,193 
3.7% at 
baseline had AF 





Age 67.4 y, MI + LV dysfunction; 
n = 5,477 
 
12% at baseline 
had AF 
 







5.2 Impact of atrial fibrillation on mortality and morbidity  
In Study II, cardiovascular morbidity and mortality were significantly more frequent in 
patients with new-onset AF than in those with persistent SR. Patients with new AF had in 
the adjusted model more often the primary composite endpoint (HR 1.88, p < 0.001), 
cardiovascular mortality (HR 1.57, p = 0.021), stroke (HR 2.82, p < 0.001) and heart 
failure (HR 4.96, p < 0.001). In the new-onset AF patients, those who were losartan-
treated had a 40% lower rate of subsequent composite events compared to atenolol-treated 
patients (p = 0.03). There were fewer strokes (HR 0.49, p = 0.01), a trend toward fewer 
myocardial infarctions (HR 0.60, p = 0.16) and no difference in cardiovascular mortality 
between losartan- and atenolol-treated patients with new-onset AF. On the other hand, 
atenolol-treated patients with new-onset AF had fewer hospitalizations for HF (HR = 0.43, 
p = 0.004) and a trend toward fewer sudden cardiac deaths (HR = 0.22, p = 0.07). 
 
Both baseline AF and new-onset AF were independent predictors of increased risk of 
total mortality, cardiovascular death and stroke in Study III. New-onset AF was associated 
with increased risk for 30-day mortality and stroke (HR 3.83, p < 0.001 and 14.6, p < 
0.001), respectively; the absolute risk of death being almost 20% and the risk of stroke 
about 12% during the first month after AMI in patients with  new-onset AF (Figure 9). 
 
 
Adjusted Hazard Ratio (95% CI) 30 Days
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Figure 9. Adjusted risk associated with new-onset AF in the OPTIMAAL-trial (Study III)             
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5.3 Restoration and maintenance of sinus rhythm in patients with 
their first CV 
One hundred and eighty-three patients underwent their first elective CV in Helsinki City 
Hospital during the one-year study period. CV was successful in 153 cases (84%). One-
year maintenance rate of SR was 22% in all patients and 25% in those patients who had a 
successful CV. Age, hypertension, coronary artery disease, heart failure, valvular disease, 
weight, height and body mass index were not found to be associated with either restoration 
or maintenance of SR after the CV. Furthermore, in the subgroup of patients in whom 
echocardiography was performed, none of the echocardiographic parameters were 
associated with the outcome. The outcome in patients with lone AF was not better 
compared to the other patients. To study whether there was any association between the 
restoration and maintenance and the delay from the diagnosis of AF to cardioversion, 
patients were divided into two groups on the basis of the median delay of 78 days. After 
one year, 29% of the patients with a shorter delay maintained the restored SR, compared 
to 16% of the patients with a longer delay (HR 0.65, 95% CI 0.45 - 0.94, p = 0.047 in log 
rank, p = 0.022 in multivariate modeling) (Figure 10).  
 
 
Figure 10. Restoration and maintenance of sinus rhythm after first cardioversion. The patients 
have been divided into two groups by median delay (78 days) from diagnosis of atrial 
fibrillation to the cardioversion. p = 0.022 in Cox proportional hazards modeling. 
Three groups were large enough to allow comparisons to estimate the association of 
anti-arrhythmic medication on maintenance of SR. Patients treated with sotalol maintained 
SR significantly more often than patients who were treated with other -blockers (p < 
0.001 both in log rank and multivariate modelling), or patients who had no anti-arrhythmic 








Figure 11. Maintenance of sinus rhythm. Patients divided into three groups according to 
medication. P < 0.01 between sotalol and both the other groups. 
5.4 Incidence of new-onset AF and losartan  
In Study II, the association of the randomisation group and the incidence of new AF was 
evaluated. New-onset AF occurred in 150 losartan- (6.8 per 1,000 person-years) and 221 
atenolol-treated patients (10.1 per 1,000 person-years). Though the analysis of AF was not 
specified in the primary LIFE study analysis plan, evaluation of treatment effects in the 
subgroup of patients with new-onset AF was a planned secondary analysis before study 
termination. Randomisation to losartan remained significantly associated with lower 
incidence of new AF also after adjustment for other considerable variables (age, male 
gender, systolic blood pressure and Cornell voltage-duration product) (HR 0.67 p < 













Figure 12. Kaplan-Meier curves illustrating ECG-verified new-onset atrial fibrillation during 
follow-up in Study II.                         
CI = confidence interval; HR = hazard ratio. 
5.5 Atrial remodeling and reverse remodeling assessed with 
magnetocardiography 
Reproducibility of the recording and analysis protocol of MCG was found to be equal in 
patients with paroxysmal AF and healthy controls in Study IV, 40 Hz overpass filtering 
giving the best reproducibility compared to 25 Hz and 60 Hz filterings. Coefficient of 
variation of MCG-measured atrial P-wave duration was 3.3% and difference between the 
measurements was on average 3.5 milliseconds, while the corresponding figures for 
simultaneously recoded SAECG were 6.1% and 6.9 milliseconds. These results of an 
agreeable reproducibility of MCG were crucial for Study V, where atrial remodeling and 
reverse remodeling were studied in cardioverted AF patients. 
 
Of the 26 patients with persistent AF 15 remained in SR after CV over the one-month 
period and were re-examined by the protocol with MCG, SAECG and echocardiography. 
Immediately after CV the AF patients had in MCG significantly longer P-wave duration 
(Pd) and larger root mean square amplitudes of the last 40 ms portion of the P-wave (P 
RMS40) in comparison to controls. Pd dispersion (standard deviation of Pds of the 
included MCG channels and ECG-leads) in SAECG was larger in AF patients. In 
echocardiography AF patients had significantly lower left and right ventricle filling A-
wave velocities immediately after CV. Likewise, LA and right atrial (RA) contractions 
were decreased, and LA diameter as well as LA and RA areas were larger when compared 
to controls (Tables 2 and 3). Examples of MCG recordings in a patient immediately after 








Figure 13. Examples of MCG and SAECG recordings in a patient immediately after and one 
month after the CV and in a representative control. 
(A) Superimposed averaged P-wave of all included MCG-channels. (B) Spatial 
magnitude of MCG channels. (C) 40 Hz high-pass filtering of MCG spatial magnitude 
with automatically determined P-wave onset and offset (vertical bars). (D) Vector 
magnitude of SAECG. (E) 40 Hz high-pass filtering of SAECG vector magnitude with 
automatically determined P-wave onset and end. 
After CV in patients who restored SR an improvement or reverse remodeling towards 
the values of the control group was detected in MCG, SAECG and echocardiography. LV 
and RV filling A-waves increased and the RA area and Pd dispersion in SAECG 
decreased significantly in AF patients. A trend of MCG-measured P-wave shortening and 
LA-diameter decrease in echocardiography was noticed. Pd in MCG, LA diameter and 
atrial areas in AF patients were still different from controls at re-examination after one 
month, emphasising that although reverse remodeling was documented, patients with a 
history of persistent AF still had significant abnormalities (Tables 2 and 3). In clinical 
practice as well as in Study I it has been noticed that the risk of AF relapse is highest 
during the first month after CV. The increased risk of AF relapse soon after CV is thought 
to arise from electrical remodeling, and rapid reduction of this risk is supposed to arise 
from reversal of electrical remodeling (Stafford et al. 1998, Hobbs et al. 2000, Chalfoun et 
al. 2007). If a patient remains in SR for one month, the risk of AF decreases and it is 
approximately 10-20%/year, which still is much higher compared to a population without 






Table 2. Atrial signal measurements of the patients at baseline and one month after 
cardioversion in comparison with age-matched control subjects.  
The values are means (SD). P-values refer to comparison with controls. All the p-values are from 
covariate analyses, where age and left atrial diameter were included as covariates. Pd, P-wave 
duration; MCG, magnetocardiography; SAECG, signal-averaged ECG; RMS40, root mean square 
of the last 40 ms of the high-pass filtered P-wave; fT,  10-15 tesla. 
 Patients with atrial fibrillation Controls 
 After conversion to SR After 1 month in SR  
 N=26 p N=15 p N=24 
Pd in MCG; ms  122.8 (18.2) 0.0017 117.4 (18.2) 0.027 101.5 (14.6) 
Pd in SAECG; ms  127.1 (12.7) 0.15 123.9 (13.3) 0.33 117.9 (12.6) 
Pd dispersion in MCG; ms  20.4 (6.6) 0.16 17.5 (8.1) 0.44 18.9 (6.4) 
Pd dispersion in SAECG; ms  18.1 (10.8) 0.040 11.0 (6.6) 0.92 12.3 (8.1) 
P RMS40 in MCG; fT 60.4 (28.2) 0.021 50.1(23.0) 0.78 46.9 (19.1) 
Table 3. Doppler echocardiographic measurements of the patients at baseline and one 
month after cardioversion in comparison with age-matched control subjects. 
The values are means (SD). P-values refer to comparison with controls. LA, left atrium; RA, right 
atrium; contraction, systolic area minus diastolic area. 
 
Patients with atrial fibrillation 
 
Controls  
 After conversion to SR After 1 month in SR  
 N = 26 p N = 15 p N = 24 
Left atrial diameter; mm  42.8 (5.1) 0.0011 41.7 (4.3) 0.043 37.6 (4.9) 
Ejection fraction; % 56.8 (5.4) 0.036 59.3 (5.1) 0.61 61.3 (6.2) 
Mitral A-wave velocity; m/s  0.27 (0.12) <0.001 0.52 (0.14) 0.58 0.58 (0.17) 
Tricuspid A-wave velocity; m/s  0.28 (0.07) <0.001 0.39 (0.09) 0.79 0.38 (0.08) 
LA area; cm2  24.8 (4.2) <0.001 23.1 (4.3) 0.050 19.3 (3.8) 
LA contraction; cm2  4.2 (1.9) 0.0034 5.3 (1.7) 0.46 5.4 (1.5) 
RA area; cm2  22.4 (4.9) <0.001 21.3 (4.1) 0.011 17.0 (2.9) 








6.1 Atrial remodeling and epidemiology of atrial fibrillation  
The prevalence and incidence of AF varies greatly among the populations studied. In 
general population the prevalence of AF is between 1.0 - 2.0% and the incidence of AF is 
about 2.0 per 1,000 person years (Krahn et al. 1995, Go et al. 2001, Majeed et al. 2001, 
Stewart et al. 2001, Ohsawa et al. 2005, Frost et al. 2005, Miyasaka et al. 2006). In older 
populations and patients with cardiovascular diseases the values are significantly higher. 
The prevalence of AF in Study I can be estimated in perspective of the catchment areas of 
this part of Helsinki City covering 440,000 inhabitants, of whom 183 were referred for 
their first elective electrical CV because of persistent AF. It can be supposed that half of 
the patients with new AF have persistent AF, and that most of the patients with a recent 
onset AF will have CV (Kannel 1983, Levy 1999, Murphy et al. 2007). Therefore our 
figure  0.4/1,000 person years  can well be accepted as representing an estimation of the 
incidence of persistent AF in the general population in Helsinki. Remembering that in an 
individual, cardiovascular remodeling is a factor predisposing to AF, the concept of 
remodeling can be widened to populations, and one could say that epidemiology of AF 
reflects the degree of remodeling in the population and the subjects concerned.  
 
The acceptance of chronic AF is a doctor-driven decision, but obviously it also reflects 
the remodeling phenomenon, or at least is based on more advanced atrial remodeling. In 
Study I we found that female gender and older age were associated with this decision, and 
with longer duration of AF there was a trend predisposing to chronic AF. This is well in 
accordance with the findings from the AFFIRM trial and the CARAF study where 
increasing age, longer duration of AF, atrial enlargement and diagnosis of cardiomyopathy 
were associated with progression to chronic AF (Curtis et al. 2005, Kerr et al. 2005). 
 
Without structural heart disease AF is rare in populations younger than 50 years, and 
extremely rare in adolescents. The fact that AF virtually does not exist in young healthy 
hearts suggests that changes predisposing to AF occur in the atrial myocardium during 
aging. The majority of AF patients have a cardiovascular background diagnosis, most 
commonly hypertension, which is diagnosed in 50-60% of AF patients (Krahn et al. 1995, 
Kannel et al. 1998, Healey and Connolly 2003). Years or decades of elevated left 
ventricular pressure enhances left ventricular stiffness, impairs left ventricular diastolic 
function and causes LVH; as a consequence, left atrial pressure is increased, predisposing 
to atrial enlargement and spontaneous electrical activity (Healey and Connolly 2003). The 
importance of LVH was underlined in a substudy of the LIFE trial where it was found that 
regression of LVH on ECG was a predictor of lower incidence of new-onset AF regardless 
of the intensity of blood pressure lowering or treatment modality (Okin et al. 2006).  
 
The other cardiovascular diseases significant at population level, such as coronary 






patients and are diagnosed in 5-25%. All those conditions have some similarities when 
regarded as risk factors for AF. Firstly, hypertension as an independent cause of AF is also 
most often diagnosed along with coronary artery disease, valvular disease and heart 
failure. Secondly, all those diagnoses take a considerable time, most often years to develop 
as symptomatic diseases, with remodeling occurring in the atria at the same time because 
of increased atrial pressure and stretch. Additionally, because of improved survival of 
patients with cardiovascular diseases, aging is associated with a vast number of patients 
with hypertension, coronary artery disease, valvular disease and heart failure. Figure 14 
illustrates relations between cardiovascular diseases, aging, atrial remodeling and AF.  
 
Figure 14. Relations between atrial remodeling, cardiovascular diseases, ageing and AF. 
Aging is the most important factor that increases the frequency of AF. In the 21st 
century, the higher life expectancy will increase markedly the number of people older than 
65 years, and very markedly the number of people older than 80 years. Remembering that 
the mean age of AF patients is about 70 years and that approximately 80% of AF patients 
are older than 65 years, there will be “a growing epidemic of AF”. Because of population 
aging, the number of AF patients will be more than doubled during the next decades, at 
least in the USA (Feinberg et al. 1995, Chugh et al. 2001, Miyasaka et al. 2006). 
Accumulation of fibrous tissue on the atria and predisposition to cardiovascular diseases 
are the main mechanisms behind the increased propensity for AF with increasing ages 







In patients with AMI, the elevated prevalence and incidence of AF also reflects the 
severity of cardiovascular remodeling. The frequency of AF is higher in older patients and 
in patients with more serious heart failure (Rathore et al. 2000). In epidemiological studies 
AF has affected 10-16% of AMI patients during the index hospitalisation, and in the 
TRACE trial where, as in Study III, patients with AMI and LV dysfunction were studied, 
21% of the patients had AF before discharge (Goldberg et al. 1990, Sakata et al. 1997, 
Pedersen et al. 1999a). As a post-hoc analysis of a prospective randomised study – where 
AMI patients with the poorest prognosis could even have been excluded – we found a 
baseline frequency of AF 12%, and 18% of the patients had AF during the entire study 
period, mean 2.7 years. 
6.2 Atrial remodeling and impact of atrial fibrillation on mortality 
and morbidity 
Study I, even though unpowered to study mortality, did not suggest increased mortality in 
the patients referred for elective electrical CV. The mortality of 3 patients in 183 patient 
years is approximately the same as the probability of death in Finnish general population 
of the same age group; 15.7/1,000 person years (www.tilastokeskus.fi). In Study II where 
hypertensive patients with LVH were studied, new-onset AF was associated with an 
increased risk of cardiovascular mortality and morbidity, stroke and hospitalisation 
because of heart failure. In Study III where patients with AMI and LV dysfunction were 
studied both baseline AF and new-onset AF were associated with an increased risk of 
cardiovascular adverse events. Among those, the risk of stroke was most markedly 
increased in AF patients, and during the 30-day period after AMI the HR for risk of stroke 
was 14.6 in patients with new AF. 
 
These findings are in line with published literature. In Study I, 81% of patients had a 
cardiovascular diagnosis, but they had stable, persistent AF and stable cardiac status 
during the period of the CV. Thus this cohort of AF patients in Study I was a somewhat 
selected AF population and presented a relatively healthy group of AF patients. Jahangir et 
al. evaluated a population-based cohort with lone AF for over 25 years and found no 
difference in the events compared to an age- and sex-matched population until the follow-
up was expanded to over 25 years (Jahangir et al. 2007). Vidaillet et al. also studied a 
population-based cohort of patients with their first AF episode. In about half of that cohort 
AF diagnosis was made in the hospital setting, and AF had the HR of 1.7 for overall 
mortality, the risk associated with AF being highest during the immediate period after the 
diagnosis of AF (Vidaillet et al. 2002). The VALUE trial included patients with 
hypertension and a predefined cardiovascular risk. In an analysis based on this trial 
patients with new-onset AF had HR of the study primary endpoint of 2.2 and HR of the 
risk of stroke of 2.2 compared to the patients without AF (Schmieder et al. 2008). The risk 
of cardiovascular events related to AF, especially to new AF, is accentuated in patients 
with AMI (Goldberg et al. 1990, Rathore et al. 2000). Therefore it seems that the risk of a 






with stable lone AF to the highest risk in patients with AMI and LV dysfunction when this 
acute episode is complicated by a new-onset AF. 
 
It has not, however, been solved whether AF is a cause of cardiovascular events and 
mortality, or a marker of more advanced status of cardiovascular diseases. The risk of 
stroke has a clear cause-and-consequence relationship with AF, the arrhythmia being a key 
source of stroke, at least in the elderly (Wolf et al. 1991). A clear temporal relationship 
between new AF and stroke was also found in Study III. Conversely, AF is associated 
with episodes – for example sudden cardiac death and coronary events – and also with 
overall mortality, which are not satisfactorily explained by AF (Køber et al. 2006, Marte et 
al. 2009). Furthermore, AF patients have had more complications even before the onset of 
AF, emphasising that a status predisposing to an event also predisposes to AF (Wong et al. 
2000). Therefore, it is obvious that a severe heart disease with “atrio-ventricular 
remodeling” is a risk for an event, e.g. exacerbation of heart failure, ventricular 
arrhythmias and sudden cardiac death and furthermore mortality, and is also a risk for AF.  
 
Atrial remodeling and propensity for AF as signaling ventricular disease has been 
documented by experiments where rapid ventricular pacing caused LV dysfunction and 
congestive heart failure, but compared to ventricles, atrial tissue was affected faster and to 
higher degree by injurious changes such as inflammation and fibrosis (Hanna et al. 2004). 
Additionally, in hypertensive patients left atrium enlargement has developed even before 
LVH (Miller et al. 1988). While the risk of developing AF and the risk of a cardiovascular 
episode vary a lot depending on the status of the population studied, the documented 
frequencies of AF can be regarded as markers of the extent of cardiac remodeling of a 
population.  
 
Since advancing cardiovascular diseases cause cardiac as well as atrial remodeling 
predisposing to AF, AF can be understood as an indicator of more serious cardiovascular 
status and should be taken into consideration in treatment decisions. Associations between 
cardiovascular status, the risk of new-onset AF and the risk of cardiovascular events were 
also documented in Studies II and III. The associations between incidences of new AF and 
incidences of stroke and mortality in different clinical studies are illustrated in Figures 15 
and 16. The source of the data of these figures is a group of prospective randomised 
studies where the frequencies were given acceptably; these data are shown in the 
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Figure 15. Incidences of new AF and stroke in ten clinical trials with renin-angiotensin-
aldosterone system-suppressing agents. Pearson’s correlation matrix 0.89, p < 0.001. 
 
  
Figure 16. Incidences of new AF and mortality in ten clinical trials with renin-angiotensin-
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6.3 Atrial remodeling and the result of cardioversion 
Besides the fact that markers of atrial remodeling are associated with increased frequency 
of AF in patients with cardiovascular diseases, atrial remodeling also hampers the efforts 
to restore and maintain SR in AF patients (Olsson et al. 1971, Ewy et al. 1980, Verhorst et 
al. 1997, Alt et al. 1997, Raitt et al. 2006). In Study I, patients with longer duration of AF 
and consequently longer period of exposure to atrial remodeling because of AF, had 
poorer restoration and maintenance of SR. The other clinical endpoint, acceptance of 
chronic AF, was observed more often in women and in older patients, while a longer 
duration of AF before the CV had a trend of being associated with this clinical decision. In 
Study V, the evaluation of predictors of restoration and maintenance of SR was not 
possible due to a limited number of patients. 
6.4 Atrial remodeling and the renin-angiotensin-aldosterone 
system  
The RAA-system is activated in hypertension and heart failure. The endproduct of RAAS, 
AngII, causes vasoconstriction, cardiac hypertrophy and fibrosis as well as endorses 
inflammation and causes electrophysiological changes (Felmeden and Lip 2000, Boos and 
Lip 2005, Schmieder et al. 2007). All these phenomena cause alterations predisposing to 
AF. Numerous studies have revealed that suppression of RAAS has an antifibrillatory 
effect on the atria and decreases the incidence of AF as well as increases the likelihood of 
SR in AF patients (Healey et al. 2005, Anand et al. 2006, Nattel et al. 2008). Formation of 
fibrosis in the atrial tissue of patients with cardiovascular diseases is enhanced, and 
antifibrotic properties are probably the main effect of those drugs preventing AF (Frustaci 
et al. 1997, Everett and Olgin 2007, Burstein and Nattel 2008). The finding from Study II 
where the incidence of new AF was decreased with an ARB, losartan, is well in line with 
these results. This is the first published result of an antihypertensive drug to decrease the 
likelihood of AF weighed against an active drug when losartan was compared to a -
blocker, atenolol. Losartan has been superior to atenolol in reducing left atrial diameter, 
and markers of atrial fibrosis have been significantly decreased with losartan, but not with 
atenolol (Ciulla et al. 2004, Gerdts et al. 2007).  
6.5 Atrial remodeling and reverse remodeling 
If atrial remodeling causes AF and also enhances the risk of AF relapse after restoration of 
SR, avoidance of remodeling and facilitating reverse remodeling would have a central role 
in prevention of AF. Avoidance of atrial remodeling due to cardiovascular diseases should 
include good primary prevention and prompt interventions to diagnose and treat those 
diseases in the best way achievable. Because of the great importance of hypertension in 






prevention of high blood pressures and urgent management of hypertension. Like the 
treatment of hypertension, also the treatment of heart failure with RAAS suppressing 
agents has the best evidence to suppress cardiovascular or atrio-ventricular remodeling 
and also to reduce the frequency of AF. If AF is diagnosed and the rhythm strategy  
restoration and maintenance of SR  is followed, SR should be restored as soon as 
possible to avoid atrial remodeling caused by AF itself (Van Gelder and Hemels 2006).  
 
Atrial remodeling and reverse remodeling in all of their aspects – electrical, structural 
and functional remodeling – were documented in Study V. As an indicator of electrical 
reverse remodeling, MCG-measured P-wave was shortened in AF patients, while 
structurally, atrial dimensions were reduced, and functionally, atrial pump function was 
increased after CV. The finding of a significantly remodeled atrial P-wave recorded with 
MCG in AF patients when compared to a comparable control group was new. This finding 
proves MCG to be a valuable tool in assessing atrial electrical remodeling non-invasively. 
Shortening of P-wave in MCG, albeit not significantly, was documented after CV toward 
the values seen in the control group, but this reverse remodeling was incomplete and not 
enough to achieve a normal duration of P-wave. In the study of Manios et al. shortening of 
P-wave was also recorded during a one-month period after CV, and they found that the 
duration of the P-wave achieved the level of their control group. However, this study was 
performed with 12-lead paper ECG (Manios et al. 2000). With signal-averaging 
techniques – either SAECG or MCG – reverse electrical remodeling has not been 
documented in a study including a control group. Atrial dimensions also remained larger 
in AF patients. These findings suggest that patients who have had persistent AF, have 
long-lasting atrial electrical and structural properties predisposing to AF. 
6.6 Clinical implications 
AF is not a rare arrhythmia in general population, and it is very frequently diagnosed in 
patients with cardiovascular diseases, such as hypertension and AMI. If the status of those 
diseases is more severe, AF and especially new-onset AF is associated with an increased 
risk of stroke and mortality. Cardiovascular diseases such as hypertension, coronary artery 
disease and heart failure cause cardiovascular or atrio-ventricular remodeling that is more 
evident in the atria. The strong associations between more serious cardiovascular status, 
AF and cardiovascular events implicate a common factor behind those phenomena, the 
atrio-ventricular remodeling most probably being that factor. RAAS-suppressing 
medication has the best evidence of primary prevention of AF and it has also improved the 
restoration and maintenance of SR. Due to the nature of AF being atrial remodeling, 
rhythm control approaches aimed at restoring and maintaining SR are always too late 
when the arrhythmia is apparent, and a substantial number of patients remain in AF. To 
improve the outcome, SR should be restored with no delay, since patients with long-
lasting AF tend to have enduring atrial electrical and structural remodeling changes 








1. SR was restored in the majority of the patients (84%) referred for their first 
elective electrical CV due to new-onset AF. Of those who had successful CV only 25% 
maintained SR for one year. Duration of AF and sotalol therapy were the only predictive 
factors of a better outcome. During the one-year follow-up period chronic AF was 
accepted in 40% of the patients. 
 
2. Hypertensive patients with LVH and new-onset AF had a significantly 
higher rate of cardiovascular events, stroke and cardiovascular mortality, and a trend of 
increased total mortality. Treatment with losartan reduced the rate of new-onset AF by 
33% as compared to atenolol therapy with similar blood pressure reductions. 
 
3. Twelve percent of patients in AMI population with LV dysfunction had AF 
and 7.2% developed new-onset AF during the mean follow-up of 2.7  0.9 years. Older 
patients and patients with more severe cardiovascular disease had and developed AF more 
often. Patients with new-onset AF had a significantly higher risk of stroke and total 
mortality.  
 
4. Atrial P-wave was reproducibly recorded and analysed with multichannel 
MCG both in AF patients and healthy controls. Reproducibility of an automated analysing 
method of MCG was not inferior in comparison with SAECG.  
 
5. Atrial electrophysiological remodeling can be detected non-invasively with 
multichannel MCG in patients with persistent AF after electrical CV. When SR was 
maintained for one month reverse remodeling was observed, but there were still 
significant differences as compared to recordings from an age-matched control group with 
no history of AF. 
 
Based on our results and the literature, AF is not a rare condition in either general 
population or patients with hypertension or AMI, and it is associated with increased risk of 
morbidity and mortality. Therefore, atrial remodeling that increases the likelihood of AF 
and also seems to be relatively stable has to be identified and prevented. RAAS-
suppressing medications appear to be the most promising method to prevent atrial 
remodeling and AF.  
 
Maintaining AF atrial remodeling is crucial  and reverse atrial remodeling is vital for 







This work was carried out from 1997 to 2009 at Maria Hospital of Helsinki City Hospital, 
at the Division of Cardiology and the BioMag Laboratory of Helsinki University Central 
Hospital and at the Laboratory of Biomedical Engineering of Helsinki University of 
Technology (HUT). During these years I have received help from a vast number of people. 
 
I am very grateful to Professor Markku S. Nieminen, MD, PhD, for the excellent 
facilities for research in the Division of Cardiology at Helsinki University Central 
Hospital. He has constantly encouraged me during my research work as well as my 
residence years in cardiology. His international contacts were indispensable for the 
completion of Studies II and III. 
 
I have had the greatest privilege to have two exceptional supervisors to guide this 
Thesis. Docent Mika Laine, MD, PhD, is an exceptional scientist and clinician, and also 
has substantial skills in sudoku. His door has always been open for discussion and his 
mind open for new ideas. I also express my deepest gratitude to my other supervisor, 
Docent Liisa-Maria Voipio-Pulkki, MD, PhD, who has an excellent career in science. I am 
very grateful for her continuous help and constructive criticism. 
 
I am particularly indebted to my previous superior, Docent Risto Kala, MD, PhD. This 
Thesis was started with him and his continuous support and sense of humour have guided 
me through all these years. His role was essential for the completion of the manuscript of 
this Thesis. Although this work has taken time he has always believed in me.  
 
I express my warmest thanks to my co-authors; Raija Jurkko (Koskinen), MD, for her 
powerful impact on inexhaustible development of MCG measurement and analysis 
methods; Docent Lauri Toivonen, MD, PhD, for his most intelligent remarks and never-
ending enthusiastic guidance in problems in science as well as in clinical work; Hannu 
Parikka, MD, PhD, for his extremely concise and practical interpretations of my writings. 
 
To carry out Studies II and III my international co-authors had an essential role. I am 
especially grateful to Kristian Wachtell, MD, PhD, who integrated me in the analyses of 
AF of the LIFE trial and appreciated my contribution to the manuscript. Kenneth 
Dickstein, MD, PhD, and Karl Swedberg, MD, PhD, had a key role in the analyses and 
completion of the manuscript of Study III. Steven Snapinn, MS, PhD, executed 
exceptional work with statistics during the process of Study III.  
 
I wish to extend my warmest thanks to my co-authors and researchers of biomedical 
engineering at the BioMag Laboratory and the Laboratory of Biomedical Engineering of 
HUT; Ville Mäntynen, MSc, Heikki Väänänen, MSc and Juha Montonen, DSc. Their 
continuous assistance with technical problems and fast and understandable answers even 
to unintelligent questions about electromagnetism have been irreplaceable. I am incredibly 






MD, PhD and to the head of the the Laboratory of Biomedical Engineering of HUT 
Professor Risto Ilmoniemi, DSc. 
 
My official reviewers Docent Heikki Mäkynen, MD, PhD, and Docent Paavo 
Uusimaa, MD, PhD, have improved the manuscript of this Thesis to a large extent with 
their very constructive, exact and valuable involvement. I express my warmest gratitude to 
them for the very fast reviewing work. 
 
I am very grateful to Pirkko Syvänen, MD, and Anna Vuolteenaho, MA, for reviewing 
and correcting the language of the Thesis. 
 
I am immensely thankful to study nurses Suvi Heikkilä, Hanna Ranne and Gun-
Christine Svahn for their outstanding help with the study patients. 
 
In addition to research work I have been working in clinics during these years, first in 
internal medicine and thereafter in cardiology. During that period I have met and got to 
know a large number of medical doctors, but also some great physicians, clinicians  or 
healers. All of them are not “doctors” or “docents”; however, they have astonished me 
with their endless passion for teaching a younger colleague. Martti Salminen, Esa Kilkki, 
Petri Hirvonen, Pekka Anttila, Risto Pajari, Sami Pakarinen, Matti Mänttäri, Markku 
Kupari, Heikki Turto, Juha Virolainen, Olavi Lammintausta and Jorma Kokkonen have 
not only impressed me with their medical skills and knowledge but also with the 
atmosphere of mutual respect they have achieved with patients. Thank you. 
 
I wish to extend thanks to all my colleagues, workmates and especially to my friends 
for their infinite support and exhortation during this work. Now is the time to get together 
and celebrate. 
 
My parents, Esko and Inkeri, and my sister Tiina deserve my most heartfelt gratitude, 
not only for the support during this task but also for their love throughout my life. 
 
Finally, I owe my most intimate gratitude to my wonderful wife Johanna and our 
daughters Sanni and Aino for their never-failing love and patience. From now on I 
promise to have more time for you. 
 
This Thesis was supported by grants from the Finnish Foundation for Cardiovascular 
Research, Aarne and Aili Turunen Foundation, Aarne Koskelo Foundation, Finnish 
Medical Society Duodecim and Helsinki University EVO Foundation. 
 
 





















Table 4. Summary of core studies evaluating the prevalence of atrial fibrillation 
Reference / Study Town/Region,  Country Population Symbol in Prevalence of AF (%) 
   Figure 1. < 60 y 60-70 y 70-80 y > 80 y overall 
Tecumseh, MI, USA 5,129, RC, ≥ 16 y  0.13 1.3 4.1 2.9 0.43 Ostrander 1965 
Go 2001 / ATRIA  
 
California, USA 1.89 million, Kaiser Permanente (health 
 maintenance organisation), ≥ 20 y 
■ 0.19 1.5 4.6 8.2 0.95 
Majeed 2001 England and Wales, GB 1.5 million, GP practices, > 0 y ▲ 0.181,1.42 3.93 7.94 10.85 1.2 
Murphy 2007 Scotland, GB 0.36 million, GP practices, > 0 y x 0.0861, 1.12 3.13 6.24 7.15 0.87 
Ohsawa 2005 300 districts in Japan 23,713, RC, ≥ 30 y ж 0.2* 1.1 na. 2.96 0.8* 
Stewart 2001 Renfrew/Paisley, Scotland, GB 15,406, RC, 45 - 64 y ● 0.5**7 1.2**8 na. na. 0.65 
Wilhelmsen 2001 Göteborg, Sweden 7,495, random cohort of men, 47 - 59 y + 0.749 4.23 8.010 na. 0.749 
Wolf 1991 / FHS  Framingham, MA, USA 5,070, RC, 50 - 89 y  0.539 1.8 4.8 8.811 2.1 
Rotterdam, Netherlands 7,983, RC, ≥ 55 y ▬ 0.712 2.1 7.3 15.4 5.5 Heeringa 2006 
Four USA communities 5,201, Medicare lists, ≥ 65 y  na. 4.013 5.8 7.3 5.4 Furberg 1994 / CHS 
RC = regional cohort, db. = database, GP = General Practitioner, FHS = Framingham Heart Study, CHS = Cardiovascular Health Study, y = years,  
* Estimation from the table, ** estimation from the figure. 
1 0 - 54 years, 2 55 - 64 years, 3 65 - 74 years, 4 75 - 84 years, 5 ≥ 85 years, 6 ≥ 70 years, 7 45 - 59 years, 8 60 - 64 years, 9 50 - 59 years, 10 75 – 79,  
11 80 - 89 years, 12 55 - 59 years, 13 65 - 69 years. 





Table 5. Summary of core studies evaluating the incidence of AF 
Reference / Study Town/Region,  Country Population Symbol in Incidence of AF (per 1,000 person years) 
   Figure 2. < 60y 60-70 y 70-80 y > 80 y overall 
Rochester, MN, USA 124,000, RC (Olmsted County,  
Mayo Clinic), ≥ 18 y 
▲ 1.8*1 9.9 2 213 344 3.4 
Miyasaka 2006 
Framingham, MA, USA 4,731, RC, 55 – 94 y ■ 5.0 ***5 14*** 2 33*** 3 69***6 na. Benjamin 1994 /  FHS 
Göteborg, Sweden 7,495 cohort of men, 47 - 59 y ▬ 2.0 5 5.82 1711 na. na. Wilhelmsen 2001 
Frost 2005 Copenhagen and Aarhus, Denmark 47,589 cohort of The Danish 
National Registry of Patients, 
50 – 64 y 
+ na. na. na. na. 2.0 
Rotterdam, Netherlands 7,983, RC, ≥ 55y ● 1.112 4.5 13 20 9.9 Heeringa 2006 
Manitoba, Canada 3,983 men, 18 – 62 y, mean 31 y x 0.8*** 4*** 9*** 16.913 2.0 Krahn 1995 / MFUS 
Four USA communities 5,201, Medicare lists, ≥ 65 y  na. 1114 20 41 19 Psaty 1997 / CHS 
Scotland, Great Britain 0.36 million, GP db.,  > 0 y  0.17, 1.15 3.22 6.23 7.74 0.9 Murphy 2007 
Great Britain 0.70 million, GP db., 40 – 89 y  0.2 1.5*** 4.0*** 8.68 1.7 Ruigómez 2002** 
 
* Estimation from the table, ** only chronic AF included, *** estimation from the figure. 1 < 65 years, 2 65 - 74 years, 3 75 - 84 years, 4 >85 years,  
5 55 - 64 years, 6 85 - 94 years, 7 < 54 years, 8 80 - 89 years, 9 45 - 59 years, 10 60 - 64 years, 11 75 - 79 years, 12 55 - 59 years, 13 by 85 years,  
14 65 - 69 years. RC = regional cohort, FHS = Framingham Heart Study, db. = database, GP = General Practitioner, CHS = Cardiovascular Health Study, 












Table 6. Main data of the studies for Figures 15 and 16. 
Study Incidence of 
AF 
Risk of CV 
endpoint 
Risk of stroke Mortality 
LIFE (Study II) 6.8 / 1,000 py. 
on Losartan 
10.1 / 1,000 py. 
on Atenolol 
23.8 / 1,000 py. on 
Losartan 
27.9 / 1,000 py. on 
Atenolol 
10.8 / 1,000 py. on 
Losartan 
14.5 / 1,000 py. on 
Atenolol 
17.3 / 1,000 py. on 
Losartan 




*7.2% / 3.0 years na. 5.0% / 3.0 years 17% / 3.0 years 
VALUE 
(Julius 2004,  
Schmieder 2008) 
3.7% / 4.2 years 
on Valsartan 
4.3% / 4.2 years 
on Amlodipine 
10.5% / 4.2 years 
4.2% / 4.2 years on 
Valsartan 
3.7% / 4.2 years on 
Amlodipine 
11.0% / 4.2 years 
on Valsartan 





5.6% / 38 
months on 
Candesartan 
6.7% / 38 
months on Pla. 
30% / 38 months on 
Candesartan 
35% / 38 months on 
Pla. 
3.7% / 38 months 
on Candesartan 
3.8% / 38 months 
on Pla. 
23% / 38 months 
on Candesartan 




*2.2% / 6.1 years na. 3.1% / 6.1 years na. 
STOP-H-2 
(Hansson 1999b) 





5.1% / 23 
months on 
Valsartan 
8.0% / 23 
months on Pla. 
28.8% / 23 months 
on Valsartan 
32.1% / 23 months 
on Pla. 
na. 
19.7% / 23 months 
on Valsartan 




Salehian 2007)  
*2.1% / 4.5 years 
 
14.0% / 4.5 years on 
Ramipril 
17.8% / 4.5 years on 
Pla. 
3.4% / 4.5 years on 
Ramipril 
4.9% / 4.5 years on 
Pla. 
10.4% / 4.5 years 
on Ramipril 






*6.7% / 56 
months 





*6.3% / 56 
months 
15.7% / 56 months 
on Telmisartan 
17.0% / 56 months 
on Pla. 
3.8% / 56 months 
on Telmisartan 
4.6% / 56 months 
on Pla. 
12.3% / 56 months 
on Telmisartan 
11.7% / 56 months 
on Pla. 
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